Volati’s board of directors has resolved on acquisitions of own ordinary shares

The board of directors of Volati AB (publ) has, based on the authorisation from the annual general meeting, today on 16 May 2018 resolved that the company can acquire a maximum of 3 000 000 own ordinary shares on Nasdaq Stockholm.The purpose of the share repurchases is to achieve flexibility to enable a more optimised capital structure. Terms and conditions for acquisitions of own ordinary shares The company’s acquisitions of own ordinary shares shall, pursuant to the board of directors’ resolution, be made on Nasdaq Stockholm in accordance with the rules set out in Nasdaq Stockholm’s Rule Book for Issuers and the following terms and conditions. 1. Acquisitions may be made on one or several occasions until the annual general meeting 2019. 2. A maximum of 3 000 000 ordinary shares may be acquired. The company’s holding of own shares may not at any time exceed one tenth of all shares in the company. 3. Acquisitions may be made at a price within the registered price interval at any given time. 4. Acquired ordinary shares shall be paid in cash. The purpose of acquisitions of own ordinary shares The purpose of the acquisitions shall be to achieve flexibility regarding the company’s equity and thereby enable an optimised capital structure. Total number of shares in the company and the company’s holding of own shares As of today on 16 May 2018, the total number of shares in the company is 82,010,345 shares, of which 80,406,571 are ordinary shares and 1,603,774 are preference shares. The company does not hold any own shares. Reporting of and information on acquisitions of own ordinary shares Acquisitions of own ordinary shares will be reported in accordance with applicable laws and regulations as well as Nasdaq Stockholm’s Rule Book for Issuers. Information on completed acquisitions will also be available on the company’s website, www.volati.se. For further information, please contact: Mårten Andersson, CEO Volati AB (publ), +46 (0)72 735 42 84, marten.andersson@volati.se  Volati AB (publ) Engelbrektsplan 1, SE-114 34 Stockholm, Sweden Tel: +46 (0)8 21 68 40, email: info@volati.se, Company reg. no 556555-4317 This information is information that Volati AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 6.00 p.m. CEST on May 16, 2018.

Resolutions at Precise Biometrics’ annual general meeting 2018

ELECTION OF BOARD MEMBERS, CHAIRMAN OF THE BOARD AND AUDITORIn accordance with the Nomination Committee´s proposal, the AGM resolved to re-elect Anna Almlöf, Torbjörn Clementz, Torgny Hellström, Matts Lilja, Mats Lindoff and Synnöve Trygg as Board members. Torgny Hellström was re-elected as Chairman of the Board.The accounting firm EY was re-elected as auditor of the company for a mandate period of one year, with the authorized public accountant Johan Thuresson as auditor in charge.In accordance with the Nomination Committee’s proposal, the AGM resolved on fees entailing that the Chairman of the Board shall receive SEK 545,000, that each of the other five members of the Board shall receive SEK 190,000 and that remuneration for committee work shall amount to SEK 35,000 for members of the Audit Committee, SEK 70,000 for the Chairman of the Audit Committee and SEK 25,000 for members and Chairman of the Remuneration Committee.DIVIDENDSIt was resolved that no dividends should be paid for the financial year of 2017.GUIDELINES FOR REMUNERATION TO SENIOR MANAGEMENTIn accordance with the proposal of the Board, the AGM resolved to adopt guidelines for remuneration to senior management principally entailing that remuneration and terms of employment shall be competitive and in accordance with market conditions. In addition to fixed salary, management may also receive variable salary, which shall be based on the company’s result and possibly individual goals. The variable part of the salary may amount to a maximum of 75% of the fixed salary for the managing director and 50% of the fixed salary for the other members of senior management. Remuneration may also be paid by way of warrants and other share-related incentive programs. AUTHORIZATION FOR THE BOARD TO RESOLVE UPON NEW ISSUES OF SHARES AND/OR CONVERTIBLESIn accordance with the proposal of the Board, the AGM resolved to authorize the Board to decide on new issues of shares and/or convertibles. Such issue may entail a deviation from the shareholders' preferential right for payment in cash, in kind and/or through set-off. The issue may result in an aggregate increase in the share capital corresponding to the issue of a maximum of 36,023,146 shares and/or convertibles to be converted into a maximum of 36,023,146 shares. Full exercise of the authorization, and where applicable full conversion, is equivalent to a dilution of approximately 10% of the current share capital and votes. The purpose of the authorization and the reason for the deviation from the shareholders’ preferential right is to enable the company, by way of issues of new shares/convertible bonds for payment in cash, in kind or through set-off, to strengthen the company’s capital base in connection with company acquisitions or strategic capital or other investments, and to obtain capital contributions from new owners that are considered strategically important from an operational, financial, structural or other perspective. RESOLUTION REGARDING INCENTIVE PROGRAM FOR THE COMPANY’S FUTURE CEOThe Board’s proposal regarding an incentive program for the company’s future CEO was not supported by the necessary majority at the AGM and will therefore not be implemented. FOR FURTHER INFORMATION, PLEASE CONTACTTorgny Hellström, Chairman of the Board, Precise Biometrics ABPhone: +46 733 45 13 00E-mail: torgny.hellstrom@precisebiometrics.com Göran Thuresson, CFO and acting CEO, Precise Biometrics ABPhone: +46 725 10 84 34E-mail: goran.thuresson@precisebiometrics.comABOUT PRECISE BIOMETRICSPrecise Biometrics is a market-leading supplier of solutions for convenient and secure authentication of people’s identity. We develop and sell fingerprint software that provide the market’s best user experience and security. Our solutions are used hundreds of millions of times every day by people all over the world and are marketed together with strong business partners. For more information, please visit https://precisebiometrics.com. Follow us on LinkedIn and Twitter. 

Report from the Annual General Meeting of Alimak Group AB held on 16 May 2018

Alimak Group AB held its annual general meeting on Wednesday, 16 May 2018. The main resolutions passed at the meeting were as follows. More detailed information about the contents of the resolutions may be obtained from the complete notice of the annual general meeting and the complete proposals. The notice and complete proposals are available on the Company’s website, www.alimakgroup.com. Adoption of balance sheets and profit and loss accounts It was resolved at the meeting to adopt the profit and loss account and balance sheet, as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2017. Dividend It was resolved at the meeting, in accordance with the Board’s proposal, that a dividend of SEK 2.30 per share would be paid, the record date being Friday, 18 May 2018. Dividends are expected to be distributed by Euroclear Sweden AB on Wednesday, 23 May 2018. Discharge from liability The meeting discharged the Directors and the CEO from liability towards the Company for the financial year 2017. Directors and auditors Anders Jonsson, Helena Nordman-Knutson, Joakim Rosengren and Jan Svensson were re-elected as Directors. Tomas Carlsson and Christina Hallin were elected as new Directors. Jan Svensson was elected Chairman of the Board. The registered accounting firm Ernst & Young AB was reappointed auditor of the Company. It was resolved at the meeting that the fee would remain unchanged for the period until the end of the next annual general meeting, comprising SEK 600,000 for the Chairman of the Board and SEK 300,000 each for other Director elected by the annual general meeting. In addition, SEK 100,000 is payable to the Chairman of the Audit Committee and SEK 75,000 to other members of the Audit Committee, SEK 70,000 to the Chairman of the Remuneration Committee, and SEK 50,000 to other members of the Remuneration Committee. It was resolved at the meeting that fees would be paid to the auditor in accordance with approved invoices. Guidelines for remuneration payable to senior executives  It was resolved at the meeting to adopt the guidelines for remuneration payable to senior executives, as proposed by the Board.Performance-based stock savings program for senior executives (LTI 2018)It was resolved at the meeting, as proposed by the Board, to adopt a performance-based stock savings program for senior executives, LTI 2018. The duration of the program is about three years and will be offered to 50 senior executives and key employees within the Alimak Group.In order to participate in the program, a personal investment in Alimak-shares is required. Each acquired Alimak-share gives the participant a right to, after a period of three years, be allotted a number of shares, without any payment of consideration, provided that certain performance targets on earnings per share have been reached. The maximum number of Alimak-shares which may be allotted under LTI 2018 is 73,500, corresponding to approximately 0.14 per cent the shares in the company. The maximum profit per allotted share for the participants is limited to 300 percent of the average share price when LTI 2018 is launched. Assuming complete fulfilment of the performance target and that the share price reaches the maximum SEK 560 (i.e. a 300 per cent gain on an assumed share price of SEK 140 when LTI 2018 is launched), the maximum costs for LTI 2018, including employer payroll taxes, will total approximately SEK 23.3 million which corresponds to approximately SEK 7.8 million on an annual basis. If under the same conditions only 50 per cent of the performance target is reached, the costs for LTI 2018, including employer payroll taxes, will total approximately SEK 16.8 million, which corresponds to SEK 5.6 million on an annual basis. Acquisition and transfer of own shares It was resolved at the meeting, in accordance with the Board’s proposal, to authorise the Board to, on one or more occasions until the next annual general meeting of 2019, resolve on acquisition and/or transfer of own shares, the later may be resolved on with deviation from the shareholders’ preferential rights. Acquisition of own shares must be made on Nasdaq Stockholm. Own shares may be acquired to the extent the Company’s holdings of own shares in total amounts to no more than one tenth of all shares in the Company. The reasons for the acquisition of own shares are: (i)                to increase the flexibility of the Board in connection to potential future corporate acquisitions,  (ii)              to enable share transfers of own shares to participants in LTI 2018 as well as to participants in future incentive programs, and (iii)             to enable divest holdings of shares to cover costs for LTI 2018 and future incentive programs. Transfer of own shares may be made to fulfil the purpose of item (i) and (iii). Transfer of own shares must be made either on Nasdaq Stockholm or in another manner with the maximum number of shares that may be transferred being the total number of own shares held by the Company at the time of the Board’s resolution to transfer the shares. In accordance with the Boards proposal, the annual general meeting resolved on transfer of shares to participants in the LTI 2018 with a maximum number of 73,500 shares and that the shares must be transferred according to the terms and conditions set out in LTI 2018. For further information, contact: Mathilda Eriksson, IR Manager, +46 8 402 14 41 About Alimak GroupAlimak Group is a world-leading provider of vertical access solutions for the industry and construction sectors. With a presence in more than 100 countries, Alimak develops, manufactures, sells and provides service to vertical access solutions with focus on adding customer value through greater safety, higher productivity and improved cost efficiency. The Group´s products and solutions are sold under the brands Alimak Hek, CoxGomyl, Manntech and Avanti. Alimak has an installed base of more than 67,000 elevators, hoists, platforms, service lifts and building maintenance units around the world. Founded in Sweden 1948, Alimak has its headquarters in Stockholm, 12 manufacturing facilities in 8 countries and 2,400 employees around the world. www.alimakgroup.com 


The Annual General Meeting in Bong AB (publ) held today adopted the following resolutions. Board of Directors and Auditors Re-election of Christian Paulsson, Eric Joan, Mikael Ekdahl, Stéphane Hamelin, Helena Persson, Stefan Lager and Håkan Gunnarsson as ordinary board members. Christian Paulsson was elected as Chairman of the Board. Directors’ fees were set at an amount of SEK 300,000 to the Chairman and SEK 150,000 to each of the other board members not employed with the company. Fees for committee work will be paid to the Chairman of the Audit Committee with SEK 100,000 and SEK 50,000 to each member. Election of the accounting firm PricewaterhouseCoopers AB for a one year period of mandate, consequently up to and including the AGM 2019, whereby the accounting firm has informed that authorised public accountant Lars Nilsson will be the auditor in charge. Fees to the auditors will be paid as per agreement. Disposition of result The Meeting adopted the proposal of the Board of Directors that no dividend is to be distributed for the financial year 2017 and that the results of the company of SEK 429,169,379 in total, including this year’s result of SEK -546,206,250 should be carried forward. Nomination Committee Re-election of Stéphane Hamelin (Holdham S.A.), Christian Paulsson (Paulsson Advisory AB) and Ulf Hedlundh (Svolder Aktiebolag) as members of the Nomination Committe for the AGM 2019. Stéphane Hamelin was elected Chairman of the Nomination Committee. Remuneration and Audit Committee At the subsequent statutory board meeting Christian Paulsson, Mikael Ekdahl and Stéphane Hamelin, were elected as members of the Remuneration Committee for the period up to the next statutory board meeting. Further, Mikael Ekdahl and Christian Paulsson were elected as members of the Audit Committee for the same period. Guidelines for remuneration to senior executives The AGM resolved to establish guidelines for remuneration to senior executives principally entailing that remuneration to senior executives shall consist of fixed salary, variable remuneration, other benefits and pension and that the aggregate remuneration shall be in accordance with market conditions and competitive. The variable part of the salary shall have a pre-deterimined cap and may as a fundamental principle never exceed 60 per cent of the fixed annual salary. The variable part is based on earnings and cash flow as well as individual qualitative goals. Variable remuneration shall not qualify for pension. Pension benefits shall primarily be fee based, but can also for legal reasons be income based, although not at the group management level. The retirement age is 65 years. The group management’s employment contracts include provisions governing remuneration and termination of employment. According to these agreements, employment can ordinarily cease on notice of termination by the employee within a period of notice of 4-12 months and on dismissal by the company within a period of notice of 6-18 months. On dismissal by the company, the period of notice and the period during which compensation is payable shall not together exceed 24 months. The guidelines in full are published on the company’s website. Malmö, 16 May 2018 Bong AB (publ)The Board of Directors The information was submitted for publication at 18.45 CET on 16 May 2018. For further information, contact Håkan Gunnarsson, CEO, Bong AB. Telephone (switchboard) +46 44 20 70 00. Bong is one of the leading providers of specialty packaging and envelope products in Europe and offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.1 billion and about 1,400 employees in 14 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its share is listed on Nasdaq Stockholm (Small Cap).

IRLAB - Resolutions at Annual General Meeting 2018

IRLAB Therapeutics AB’s Annual General Meeting 2018 was held today, Wednesday May 16, 2018, in Göteborg. At the Annual General Meeting the following main matters were resolved.  Disposition of the company’s results  The proposed disposition by the Board of directors of the company’s results was adopted by the Annual General Meeting. This means that the amount available to the Annual General Meeting, totaling SEK 272 878 101, shall be transferred in full and that no dividend shall be paid for the past fiscal year. Discharge from liability for the Board members and the Managing Director The Annual General Meeting resolved to discharge the Board members and the Managing Director from liability for their administration during the fiscal year 2017 Remuneration   Remuneration to the Board of directors was resolved in the amount of SEK 300 000 to the Chairman of the Board and SEK 175 000 to each of the other Board members. It was further resolved that remuneration shall be paid to the Board’s Audit Committee in the amount of SEK 75 000 to the Committee’s Chairman and SEK 50 000 to the other members of the Committee, that remuneration shall be paid to the Chairman of the Remuneration Committee in the amount of SEK 50 000 to the Committee’s Chairman and SEK 30 000 to the other members of the Committee. The Auditor’s fees shall be paid in accordance with the invoice approved by the company. Election of Board members and auditor  John D. Wakely and Lena Torelgård were elected as new Board members and Anders Vedin, Lars Adlersson, Eva Lindgren, Gunnar Olsson, Hans-Olov Olsson and Ren Piir were re-elected as Board members. Anders Vedin was re-elected as Chairman of the Board. Jacob Testor had declined re-election. The firm of auditors Öhrlings PricewaterhouseCoopers AB were elected as auditor of the company. Guidelines for remuneration to senior executives  The Annual General Meeting resolved on guidelines for senior executives in accordance with the Board’s proposal. The guidelines mainly mean that senior executives shall be offered marked-based compensation , which shall take into account the individual’s areas of responsibility and experience. The remuneration shall consist of fixed salary and pension, with the aim of promoting the company’s long-term value creation. Authorization for he board of directors to resolve upon issues of shares and/or warrants and/or convertibles The Annual General Meeting resolved in accordance with the Board’s proposal to authorize the Board to, on one or more occasions up until the next Annual General Meeting, to decide on new issue of shares and/or warrants and/or convertibles for cash payment and/or with the provision of contribution or set-off or otherwise with conditions and to therewith be able to deviate from the shareholders’ preferential rights. The new issues shall take place at a market-based subscription price determined by the Board in consultation with the company’s financial advisors, with consideration taken to market-based issue discount where applicable. The number of shares that may be issued respectively the number of shares that may be subscribed to with option rights to new subscription of shares respectively the number of shares that the convertibles shall entitle to conversion shall in total amount to a maximum of 1 230 000 shares, which corresponds to a reduced ownership interest for non-participating shareholders (dilution) amounting to 15.0 percent or an increase of the current number of outstanding shares by 17.6 percent.

Ambea interim report January-March 2018

”The year has started well with continued favourable growth in Own Management and many beds in ramp-up phase. Together with start-up units, our acquisitions made a positive contribution to sales and profitability. However, as previously announced, volume reductions in Contract Management operations had an adverse impact on performance. During the quarter, we launched our new brands: Klara for staffing solutions and Heimta for operations in Norway, which both now report as separate segments. Net sales in the first quarter amounted to SEK 1,467 million (1,422). Own Management accounted for 67 per cent (62) of net sales. Adjusted EBITA, excluding items affecting comparability, was in line with the previous year at SEK 109 million (110). As part of work improving profitability and also retaining competitiveness in the future, Ambea decided during the quarter to adapt the Group’s administrative costs. The adjustments include efficiency improvements by digitising and automating administrative procedures. The measures will have a limited impact on earnings in 2018, while we expect the full effect of savings in 2019, amounting to about SEK 30 million.” Highlights of the first quarter: · Net sales rose 3 per cent to SEK 1,467 million (1,422) · Operating profit (EBIT) increased to SEK 86 million (73) · EBITA increased 22 per cent to SEK 105 million (86), corresponding to a margin of 7.2 per cent (6.1) · Adjusted EBITA, excluding items affecting comparability decreased 1 per cent to SEK 109 million (110). · The adjusted EBITA margin was 7.4 per cent (7.7) · Items affecting comparability in the quarter amounted to SEK -4 million (-24), attributable to the divestment of personal assistance operations that was completed in the fourth quarter of 2017. · Profit for the period was SEK 60 million (33) · Earnings per share amounted to SEK 0.88 (0.52) before and SEK 0.87 (0.52) after dilution · Operating cash flow amounted to SEK 111 million (87) · Free cash flow totalled SEK 66 million (24) · Norway (Heimta) and Staffing Solutions (Klara) are reported as separate segments as of the first quarter Telephone conference: Ambea will host a presentation with the possibility to attend through a telephone conference at 10:00 (CET) today. The presentation will be held in English and will also be available as webcast on: https://edge.media-server.com/m6/p/b3wkyj2d  Dial-in information: To ensure that you are connected to the conference call, please dial in a few minutes before the conference call to register your attendance by stating “Ambea”. Sweden:                              +46 (0) 8 5033 6574UK:                                      +44 (0) 330 336 9105 US:                                      +1 323-794-2094 The interim report, presentation and other material are available on www.ambea.com

Endomines interim report January- March 2018

Endomines AB, Stock Exchange Release 17 May 2018 at 07:30 CEST Q1 2018 (vs Q1 2017)Operational highlights · Gold production was 92.1 kg (97.9) · Milled ore was 37,568 tons (40,804) at head grade of 3.0 g/t (2.9) · Cash Cost was 1,276 USD/oz (1,205) Financial highlights · Net sales were 27.4 MSEK (28.5) · EBITDA was -8.5 MSEK (-1.3) · Total cash flow was 87.1 MSEK (-11.6) · Earnings per share was 0.06 SEK (-0.80) Strategic highlights · Endomines’ rights issue was successfully completed with 189 MSEK gross proceeds · Endomines executed transactions relating to the rearrangement and repayment of its bank debt; 2 MEUR (20 MSEK) of the outstanding debt of 7.6 MEUR was written off, 2 MEUR repayment was made to the lender and the remaining debt of 3.6 MEUR was taken over by Joensuun Kauppa ja Kone and later converted to Endomines shares · Acquisition of TVL Gold with five gold projects in Idaho, USA, was completed on 27 February 2018; operating entity with the assets renamed as Endomines Idaho LLC Significant subsequent events · Endomines announced an extensive and systematically planned exploration project in the Karelian Gold Line in Eastern Finland. The intention is to conduct the project over several years. The activities planned for 2018 will largely be carried out during the next 6 months with an exploration budget of approximately 2 MEUR. · Endomines commenced co-operation negotiations with its whole personnel at the Pampalo mine in Ilomantsi, Finland, on reduction of workforce. The negotiations concern approximately 40 employees and according to initial estimates may at most lead to the lay-off for more than 90 days and/or termination of 32 employees on productional or economic grounds. Production guidance for 2018:Endomines anticipates producing 250-300 kg gold in Pampalo in January-September 2018. Production in October-December requires investment in a decline into the deep extension of Pampalo. Decision on the possible investment is expected to be made during the second quarter 2018. +--------------------------------------+-----+-----+-----+|Key figures (Consolidated) | | | |+--------------------------------------+-----+-----+-----+| | JAN-MAR |+--------------------------------------+-----+-----+-----+|MSEK if not otherwise stated | 2018| 2017| +/-|+--------------------------------------+-----+-----+-----+|Revenue | 29.4| 33.5| -4.1|+--------------------------------------+-----+-----+-----+|Cost |-37.9|-34.8| -3.1|+--------------------------------------+-----+-----+-----+|EBITDA | -8.5| -1.3| -7.2|+--------------------------------------+-----+-----+-----+|Depreciation and write-downs |-11.3| -9.6| -1.7|+--------------------------------------+-----+-----+-----+|EBIT |-19.9|-10.9| -9.0|+--------------------------------------+-----+-----+-----+|Net result for the period | 1.9|-12.2| 14.1|+--------------------------------------+-----+-----+-----+|Earnings per share (SEK) | 0.06|-0.80| 0.86|+--------------------------------------+-----+-----+-----+| | | | |+--------------------------------------+-----+-----+-----+|Cash flows from operating activities |-12.9| -3.0| -9.9|+--------------------------------------+-----+-----+-----+|Investments |-60.6| -7.8|-52.8|+--------------------------------------+-----+-----+-----+|Financing |160.6| -0.7|161.3|+--------------------------------------+-----+-----+-----+|Total cash flow | 87.1|-11.5| 98.6|+--------------------------------------+-----+-----+-----+|Liquid assets at the end of the period|103.6| 17.9| 85.7|+--------------------------------------+-----+-----+-----+|Personnel at the end of the period | 43| 43| -|+--------------------------------------+-----+-----+-----+ CEO Saila Miettinen-Lähde:“The first quarter of 2018 saw us conclude many strategically important transactions that laid the foundation for our future development and growth: we successfully completed a 189 MSEK rights issue, eliminated all bank debt, and Joensuun Kauppa ja Kone Oy became a significant investor in the Company. Furthermore, we completed the acquisition of TVL Gold that holds five gold assets in Idaho, USA, thereby expanding our international presence. Operations at our Pampalo mine proceeded according to plan during the first quarter with gold production amounting to 92.1 kg. As we had expected, production output was impacted by challenging rock conditions during the first weeks of the quarter. From mid-February onwards, the underground conditions have again improved and production as well as the gold head grade have recovered and even exceeded our budgeted levels. Overall, we are well on our way to meeting our guided production range of 250-300 kg of gold for January-September 2018. Our financial performance also reflected the challenging mining conditions, with net sales amounting to 27.4 MSEK and EBITDA to -8.5 MSEK. Following our recent financing, our financial position remains solid and allows us to proceed with our planned projects both in the USA and Finland. In April, we regrettably had to commence co-operation negotiations with our whole personnel at the Pampalo mine on reduction of workforce. Continuation of production in Pampalo after September requires a sizeable investment in the deep extension of the mine, but the current gold price appears not to support the investment decision. We therefore consider postponing the investment and temporarily suspending gold production in Pampalo. Decisions on the matter will be taken subject to the ongoing co-operation negotiations during the second quarter. Going forward, we look forward to progressing our project development in Idaho with the aim of commissioning the first of the five mines there within one year from the acquisition. During the current year, we are also planning to invest approximately 2 MEUR in exploration along the Karelian Gold Line in Eastern Finland with the target of enabling profitable gold production in the region in the longer term.” Full quarterly reportThe full quarterly report is attached to this press release as well as available on the Company´s website, www.endomines.com. Contact personSaila Miettinen-Lähde, CEO, +358 40 548 36 95, saila.miettinen-lahde(at)endomines.com This information is information that Endomines AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07:30 CEST on 17 May 2018. About EndominesEndomines is a mining and exploration company with its primary focus on gold. The Company operates a gold mine in Pampalo, has exploration activities along the Karelian Gold Line in Eastern Finland and develops mining operations in Idaho, USA. Endomines aims to improve its long-term growth prospects by increasing its exploration activities and through acquisitions. Endomines aims to acquire deposits that are situated in stable jurisdictions and can be brought to production rapidly with limited investments. The shares trade on Nasdaq Stockholm (ENDO) and Nasdaq Helsinki (ENDOM).

Japanese tech giant Ricoh enters partnership with Coloreel to revolutionize the textile industry with thread coloring innovation

Coloreel and Ricoh have cooperated for several years, and have now signed the final contracts. This partnership is a joint development effort to revolutionize the textile business, first with the thread coloring unit for the embroidery industry. "This partnership is a high profile project for us; we see much potential in this product and this industry. We believe in Coloreel and their unique technology, says Tetsuya Morita," General Manager of Commercial and Industrial Printing Development Division at Ricoh. Ricoh has been driving innovation for more than 80 years and is a leading provider of document management solutions, IT services, commercial and industrial printing, digital cameras, and industrial systems. Ricoh will build the sub-system for the colorization process using their long experience in the world of printing and combine it with Coloreel’s new technology for colorization. The development has taken place with Ricoh’s engineers in Japan, England and Coloreel’s engineers in Sweden. "The partnership with Coloreel further demonstrates our commitment to collaboration and pushing boundaries. Combining our history of driving innovation for over 80 years, our commitment to customer needs and intent on becoming the analog to digital transformation experts in industrial process is enabling us to disrupt this exciting industry, says Peter Williams," General Manager of Commercial and Industrial Printing Business Group at Ricoh. The Coloreel technology enables high-quality instant coloring of textile thread while it is in the textile production. The first product to be launched based on this technology is a groundbreaking thread coloring unit that works with any existing industrial embroidery machine. By instantly coloring a white base thread during the embroidery production, Coloreel enables complete freedom to create unique embroideries without any limitations in the use of colors. "It feels amazing that a company like Ricoh, with their dignity and size, chooses to enter this partnership with us. To have Ricoh as our partner gives our product even more credibility, and we are excited to see what this partnership will bring," says Mattias Nordin, CEO at Coloreel. Coloreel will start production in autumn 2018. World-leading companies in textile, fashion and sportswear are standing in line to use this revolutionary product.   For more information about Coloreel, visit www.coloreel.com or contact:   Mattias Nordin, CEO at Coloreel, mattias.nordin at coloreel.com (mattias.nordin@coloreel.com), +46 708 558 557 Jack Gibson, Senior Corporate Communications Executive at Ricoh Europe, jack.gibson@ricoh-europe.com, +44 (0) 203 033 3750   About Coloreel: Coloreel is a Swedish technology innovation company within the textile industry. Since 2009 the company has developed the Coloreel technology, a ground-breaking innovation that enables high-quality coloring of textile thread on demand, opening amazing new design possibilities. The technology can be used for industrial embroidery, sewing, knitting, weaving and more. Coloreel’s first product based on the technology is a thread coloring device which is created to be used with industrial embroidery machines.   About Ricoh: Ricoh is empowering digital workplaces using innovative technologies and services enabling individuals to work smarter. For more than 80 years, Ricoh has been driving innovation and is a leading provider of document management solutions, IT services, commercial and industrial printing, digital cameras, and industrial systems. Headquartered in Tokyo, Ricoh Group operates in approximately 200 countries and regions. In the financial year ended March 2017, Ricoh Group had worldwide sales of 2,028 billion yen (approx. 18.2 billion USD).

Attendo divests its healthcare operations in Finland

“We are very pleased to be able to present a long-term solution for Attendo’s Finnish healthcare operations, which I co-founded in year 2000 and that has been part of Attendo since 2007. This enables us to focus on developing Attendo’s own units and care offering in Finland and rest of the Nordics and at the same time gives the Finnish healthcare business even better opportunities to develop with Terveystalo as a dedicated new owner,” says Attendo CEO Pertti Karjalainen. The Finnish healthcare business includes staffing services, primary care, dental care, occupational healthcare and complete outsourcing of care and healthcare. The business consists of approximately 100 operating units with around 1,600 full time employees. The combined net sales in 2017 were approximately EUR 230 million with a contribution to Attendo’s operating profit (EBITA) of approximately EUR 20* million. The enterprise value of the transaction is EUR 233 million on a cash and debt-free basis. The healthcare operations will be reported as operations held for sale from the second quarter of 2018. The completion of the transaction is pending approval from competition authorities in Finland. Danske Bank acted as financial advisor and Krogerus as legal advisor to Attendo in connection with the transaction. Attendo AB (publ) For further information, please contact: Andreas Koch, Communications and IR Director AttendoPhone: +46 705 09 77 61E-mail: andreas.koch@attendo.com This is information that Attendo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 17 May 2018. *Excluding central overhead costs that remains in Attendo. ___________________________________________________________________________________________________________________________________________________________________________________________________Attendo - the leading care and healthcare company in the Nordics Attendo is the leading private provider of publicly financed care and healthcare services in the Nordic region. The company was founded in 1985 and was first to provide outsourced care for older people in Sweden. In addition to care for older people, Attendo provides care for people with disabilities, individuals and families, and, in Finland, healthcare and dental care. Attendo has more than 24,000 employees and is locally anchored with over 700 operations in more than 200 municipalities in Sweden, Finland, Norway and Denmark. www.attendo.com  Terveystalo in briefTerveystalo is a listed company on the Helsinki Stock Exchange. Terveystalo is the largest healthcare service company in Finland with net sales and network. The company offers versatile primary and secondary health care services for corporate and private customers and the public sector. The nationwide network covers 180 locations across Finland, complemented by 24/7 digital services. In 2017, Terveystalo had approximately 1.2 million individual customers and approximately 3.3 million doctor visits. Nearly 9,000 healthcare professionals work in Terveystalo, about half of whom are private practitioners. Terveystalo's services carry the Key Flag symbol and the company is a member of the Association for Finnish Work. www.terveystalo.com

Boozt AB’s Q1 quarterly report, January 1 – March 31 2018

SEK million   Q1, 2018 Q1, 2017 ChangeNet Revenue 551.9  421.1  31.1% Gross profit  215.9  187.1  15.4% EBIT  -6.4  -26.1  19.7 Adjusted EBIT  -4.1  -2.5  -1.6      Organic growth, %  31.1%  62.1% Gross margin, %  39.1%  44.4%  -5.3 pp EBIT margin, %  -1.2%  -6.2%  5.0 pp Adjusted EBIT margin, %  -0.7%  -0.6%  -0.1 pp  CEO Hermann Haraldsson says: “We have had a solid start to the year with growth in line with our expectations on the back of a strong first quarter of 2017. Although trading conditions were negatively impacted by the cold weather, the flexibility of our business model proved its worth as momentum continued but with a different sales mix than anticipated as the spring season only started towards the very end of the quarter.” "Our profitability was also in line with expectations, as the expected negative development in gross margin was offset by operational leverage. In comparison to Q1 2017 the gross margin was negatively impacted by delayed spending on full price spring items due to the cold weather, a relative smaller share of campaign goods which in Q1 2017 generated a higher gross margin and the terminated commission sales agreement with ECCO." "Based on the solid momentum and the positive impact from currency we increase our growth guidance and now expect revenue growth of more than 33% for the year. We continue to see stronger growth towards the end of the year as the categories accelerate their growth with increased focus and new brands being launched, including adidas and Reebok within Sport as well as MAC and Kiehls within Beauty. Also, worth highlighting is the strong development of Booztlet, where our dedicated efforts are beginning to unlock the potential of the off-price segment.” Outlook for 2018 The outlook for 2018 is adjusted upwards compared to the announcement of 27 February 2018 17 May 2018  27 February 2018Net More than 33%                             More than 30%revenuegrowth Adjusted Slightly      Slightly improved from 2.4%EBIT improved frommargin  2.4%  Telephone conference / audiocast Boozt’s Group CEO, Hermann Haraldsson, and Group CFO, Allan Junge-Jensen, will present the full year Report at a telephone conference / audiocast at 09.30 CET on Thursday, May 17, 2018. The presentation will be held in English and will be followed by a Q&A session. Questions can be asked via the telephone conference or in written form via the audiocast. The presentation material will be available at Boozt’s website . For additional information, please contact:   Boozt AB (publ) Hermann Haraldsson / Group CEO / Phone: +45 20 94 03 95 / Email: heha@boozt.com Allan Junge-Jensen / Group CFO / Phone: +45 41 19 70 60 / Email: ajj@boozt.com Anders Enevoldsen / Head of IR & Corporate Communications / Phone: +45 53 50 14 53 / Email: anen@boozt.com  This information is such information that Boozt AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, at 08:00 CET on 17 May 2018.

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2018

Period January – March 2018   · Revenues amounted to SEK 0.1 (0.0) million · Operating result amounted to SEK –18.8 (–22.1) million · Result after tax amounted to SEK –18.7 (–22.0) million, corresponding to SEK –0.30 per share (–0.35) before and after dilution · Cash flow from operating activities amounted to SEK –22.9 (–19.1) million · Cash and cash equivalents at the end of the period amounted to SEK 102.1 (174.1) million · Number of employees at the end of the period was 7 (7) · Number of shares at the end of the period was 62 528 433 All comparative amounts in brackets refer to the outcome during the corresponding period 2017. Significant events during January – March 2018   · Mechanism of action data for cobitolimod was presented at the European Crohn’s and Colitis Organisation (ECCO) congress · A new patent for cobitolimod will be issued in Japan Significant events after the reporting period   · InDex hosted a Capital Markets Day in Stockholm on April 25, 2018 for investors, analysts and media · InDex has developed a novel formulation of cobitolimod for oral administration “Important news that will strengthen InDex’s position in future partner discussions, is our successful development of a GMP ready capsule to be taken orally and release cobitolimod in the colon,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. CEO statement  The CONDUCT study continues to be InDex’s main focus. We work very actively with the study and visit clinics around Europe to keep them engaged in the study. We are still waiting for approval by the Romanian regulatory authority but have contracted extra clinics in the other 11 countries to reach the planned 90 clinics. InDex is actively pursuing out licensing and I very much look forward to reporting our latest advances at the BIO convention in Boston in early June. BIO is the pharmaceutical industry’s largest networking event with some 16,000 representatives from drug development companies and larger pharmaceutical companies looking for new innovative products for their portfolios. Our most important message to potential partners will be that the CONDUCT study is developing as expected and that our objective to report top line results in the fourth quarter of 2018 remains. Furthermore, we will highlight the new data on cobitolimod’s immunological mechanism of action, which received significant attention at the ECCO congress in February. Other important news, that will also strengthen InDex’s position in future partner discussions, is our successful development of a GMP ready capsule to be taken orally and release cobitolimod in the colon. Additionally, the release profile can be adjusted to target other parts of the gastrointestinal tract which are inaccessible to the topical formulation currently evaluated in the CONDUCT study. An oral version would provide added patient convenience and broaden the potential therapeutic use of cobitolimod to extensive colitis and even Crohn’s disease. Another important aspect is that the oral formulation development provides opportunities for securing additional intellectual property. InDex’s life cycle management strategy for cobitolimod is to launch first the topical formulation. The oral formulation will be a follow-on product and the next stage of its development is contingent on the results of CONDUCT. In March, a new Japanese method of use patent for cobitolimod was granted, which constitutes a valuable complement to our existing patent portfolio. A corresponding patent had already been granted in the US and patent applications have been filed or will be filed in Europe and Canada. On April 25, we successfully hosted InDex’s first Capital Markets Day. In addition to InDex’s management, two internationally prominent professors in Inflammatory Bowel Disease participated and gave their views on the medical need and cobitolimod’s potential. The videos and presentation material from the day are available on InDex’s website. On May 24, all shareholders are welcome to the Annual General Meeting of InDex and I hope to see you there. For more information:  Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: peter.zerhouni@indexpharma.com Publication  This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on May 17, 2018. InDex Pharmaceuticals in brief  InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com. 

Oncopeptides AB Interim report January – March 2018

"Important milestones have been achieved in the first quarter” Summary of Q1 Financial overview January 1 – March 31 2018  · Net sales amounted to 0.0 (0.0) MSEK · Loss for the period was 62.0 (loss: 62.1) MSEK · Loss per share, before and after dilution, was 1.56 (loss: 1.89) SEK · On March 31st cash and cash equivalents amounted to 664.9 (611.6) MSEK Significant events during the period January 1 – March 31 2018  · In March, the company strengthened its management team with the appointment of Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer · Ygalo® was granted additional patent protection in Japan in March, providing protection up until 2033 · Oncopeptides completed a directed share issue of approximately 314 MSEK before issue costs (USD 38M) in March  Significant events after the end of the reporting period  · First patient started treatment in the Phase I/II ANCHOR study with Ygalo® · In April, the company appointed a Clinical Advisory Board consisting of internationally recognized researchers within the field of clinical development of hematology Financial overview of the group +--------------------------------------------------+---------+---------+---------+|SEK thousand | 2018| 2017| 2017|| |Jan - Mar|Jan - Mar|Jan - Dec|+--------------------------------------------------+---------+---------+---------+|Net sales | –| – | – |+--------------------------------------------------+---------+---------+---------+|Operating loss | -68,451| -62,083| -247,620|+--------------------------------------------------+---------+---------+---------+|Loss before tax | -62,032| -62,083| -247,620|+--------------------------------------------------+---------+---------+---------+|Loss for the period | -62,032| -62,083| -247,620|+--------------------------------------------------+---------+---------+---------+|Earnings per share before and after dilution (SEK)| -1.56| -1.89| -6.44|+--------------------------------------------------+---------+---------+---------+|Cash flow from operating activities | -40,547| -67,637| -271,497|+--------------------------------------------------+---------+---------+---------+|Cash and cash equivalents at the end | 664,944| 611,599| 404,050||of the period | | | |+--------------------------------------------------+---------+---------+---------+|Research & development costs/operating expenses % | 82%| 76%| 80%|+--------------------------------------------------+---------+---------+---------+ Financial calendar Annual May 17, at 3.00 p.m. CET,General Tändstickspalatset, Västra TrädgårdsgatanMeeting 15, Stockholm, SwedenInterim July 13, 2018report Q2Interim October 26, 2018report Q3Year-end February 22, 2019report 2018  For further informationJakob Lindberg, CEO, Oncopeptides ABE-mail: jakob.lindberg@oncopeptides.seTelephone: +46 (0)8 615 20 40 Rein Piir, Head of Investor Relations, Oncopeptides ABE-mail: rein.piir@oncopeptides.seTelephone: +46 (0)70 853 72 92 About OncopeptidesOncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxic (PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from ­treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.   For more information visit www.oncopeptides.se. This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on May 17, 2018. 

Etrion Announces Completion of 13.2 MW Komatsu Solar Project in Japan

May 17, 2018, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, announces that the Komatsu solar project totaling 13.2 megawatts (“MW”) has commenced full commercial operation. This new solar project, built by Hitachi High-Technologies, was completed ahead of schedule and on budget.  Komatsu is a 13.2 MW utility-scale solar photovoltaic (“PV”) power project site in the Ishikawa prefecture of the Honsu region in Japan. The Komatsu site has a twenty-year power purchase agreement (“PPA”) with the Hokuriku Electric Power utility and will receive ¥32 per kilowatt-hour (“kWh”) produced (approximately US$0.30 per kWh).  The Komatsu solar project is expected to produce approximately 14.2 gigawatt-hours (“GWh”) of solar electricity per year.    Marco A. Northland, Etrion’s Chief Executive Officer, commented, “We are delighted with our continuous progress in Japan and Komatsu represents an important milestone as we reach nearly 60 MW of gross capacity now operating in Japan. I am very grateful to our team, Hitachi High-Technologies and all other stakeholders that worked around the clock to complete this project ahead of schedule, enabling Etrion to capture all the revenues during the summer, being the highest production months. It also releases internal resources which can now focus on the next projects in the backlog targeted to being construction within the next 12 months.” About Etrion Etrion Corporation is an independent power producer that develops, builds, owns and operates utility-scale solar power generation plants. The Company owns and operates 56.7 MW of solar capacity, all in Japan.  Etrion also has several projects in the backlog and pipeline at different stages of development in Japan. The Company is listed on the Toronto Stock Exchange in Canada and the NASDAQ OMX Stockholm exchange in Sweden under ticker symbol “ETX”. Etrion’s largest shareholder is the Lundin family, which owns approximately 24% of the Company’s shares directly and through various trusts. Subscribe to receive Etrion’s press releases by email as soon as they are published. Click here to subscribe   Etrion discloses the information provided herein pursuant to the Swedish Securities Market Act. The information was submitted for publication at 8:05 a.m. CET on May 17, 2018. Forward-Looking Information: This press release contains certain “forward-looking information”. All statements, other than statements of historical fact, that address activities, events or developments that Etrion believes, expects or anticipates will or may occur in the future (including, without limitation, statements relating to the expected production of electricity from the Komatsu solar project and proposed advancement of Etrion’s Japanese development activities). This forward-looking information reflects the current expectations or beliefs of Etrion based on information currently available to it as well as certain assumptions (including assumptions as to the production from the Komatsu project and Etrion’s ability to advance its growth plans in Japan). Forward-looking information is subject to a number of significant risks and uncertainties and other factors that may cause actual results to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, Etrion. Factors that could cause actual results or events to differ materially from current expectations include, but are not limited to, the risks that: the Komatsu solar project may not produce electricity in the amounts expected; Etrion may not be able to obtain all applicable permits for the development of its current Japanese development projects; Etrion may not be able to  obtain the necessary financing for such projects on economic terms and the development costs for such projects may be higher than anticipated; and Etrion may not be able to source additional projects in Japan on economic terms to the extent anticipated. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Etrion disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. Although Etrion believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty thereof.  For additional information, please visit the Company’s website at www.etrion.com or contact: Christian Lacueva – Chief Financial Officer  Telephone: +41 (22) 715 20 90

Decision on rights issue for continued growth, establishment of sales organization and commercial break-through

MOTIVE FOR THE UNITS ISSUE PHI's innovative technology creates new opportunities for medical research to improve treatment methods and results. During the last years, PHI has conducted an extensive work in order to ensure its product quality and function. Further, the company has transitioned its business model from distributor sales to direct sales in the Nordic market, which has led to a significant sales increase and margin improvement in the Nordic market. The board of PHI therefore has against the background above and also subject to approval on Extraordinary General Meeting, decided to conduct a rights issue of units (shares and warrants) which can provide the company a maximum of SEK 46.3 million prior to issue costs initially and an additional maximum SEK 18.3 million prior to issuing costs at a later stage through warrants. The units issue is conducted with the aim of achieving a positive cash flow through extended direct presence in key markets combined with primarily digital marketing, as well as attracting additional leading industry players. In order to broaden the ownership, the board also plan to decide on a so-called over-allotment option that can provide the company an additional approximately SEK 10.5 million at the most and later an additional SEK 4.2 million at the most through warrants, to be utilized if the units issue initially is over-subscribed. SUMMARY OF THE OFFERING Subscription period: June 28 – July 17, 2018.Issue price: SEK 71.40 per unit, corresponding to SEK 23.80 per share. Warrants of series TO 1 are received gratuitous.Volume of issuance: The offering consists of 1,945,014 shares and 648,338 warrants of series TO 1 at the most. Fully subscribed units issue initially provides PHI approximately SEK 46.3 million. If the initial issue is fully subscribed and all associated warrants are utilized, PHI is provided an additional SEK 18.3 million; totally approximately SEK 64.6 million prior to issuing costs.Record date: Record date is June 21, 2018. Last day of trading in PHI’s share including the right to receive unit rights is June 19, 2018. First day of trading in the share excluding the right to receive unit rights is June 20, 2018.Preferential rights: Those that on the record date June 21, 2018 are registered as shareholders in PHI have preferential rights to subscribe for units in the rights issue. Each currently held share qualifies for one unit right. 18 unit rights entitle to sub­scription of one new unit. One unit consists of three new shares and one associated gratuitous warrant of series TO 1.Shares before the rights 11 670 088 shares.issue:Valuation (pre-money): Approximately SEK 277.7 million.Subscription commitments Beforehand, PHI has agreed on subscriptionand guarantee commitments amounting to approxi­mately SEK 4.6commitments: million, corresponding to approximately 10 % of the initial issue volume and guarantee commitments amounting to approx­i­mately SEK 24.2 million, corresponding to approximately 52 % of the initial issue volume.Trading in unit rights: Will take place on AktieTorget during the period June 28 – July 13, 2018.Trading in BTU: Will take place on AktieTorget from June 28, 2018 until Bolagsverket (the Swedish Company Authority) has registered the rights issue. This registration is expected to take place in the beginning of august 2018.Over-allotment option: In order to further expand the ownership of the company, the board also plan to decide on a directed units issue, a so-called over-allotment option, of an additional approximately SEK 10.5 million at the most (with associated gratuitous warrants of an additional SEK 4.2 million at the most), to be utilized if the units issue initially is over-subscribed. For specified terms concerning the over-allotment option, please refer to “Terms and conditions” in the prospectus that will be published before the subscription period is initiated. Summary of the terms for warrants of series TO 1 · The issued warrants of series TO 1 are scheduled to be traded on AktieTorget starting mid-August 2018. · Each warrant of series TO 1 entitles to subscription of a new share at a price of SEK 28.20. · Subscription of shares on the basis of warrants of series TO 1 can be made during the period Maj 23 – June 13, 2019. Full terms and conditions, information on subscription commitments and guarantee commitments as well as the prospectus and the folder will be published on the company’s (www.phiab.se), AktieTorget’s (www.aktietorget.se) and Sedermera Fondkommission’s (www.sedermera.se) respective websites no later than when the subscription period of the offering begins. PREPONED YEAR-END REPORT Publication of PHI’s year-end report for the fiscal year 2017/18 will be preponed. Previous date for publication was June 18, 2018. New date for publication is June 12, 2018. FINANCIAL ADVISOR Sedermera Fondkommission is the financial advisor to PHI in connection with the planned rights issue. For additional information about the planned rights issue, please contact: Sedermera FondkommissionTel: +46 40 615 14 10E-mail: info@sedermera.seWeb: www.sedermera.se 

Obducat receives order from IMB – Institut di Electronica di Barcelona - CSIC

The ordered QS W 300 system, suitable for wet processing, will be installed in the cleanroom facilities of CNM-CSIC Campus UAB in Barcelona, Spain.   Delivery is planned for the third quarter this year.   This is information that Obducat AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on May 17th, 2018 at 08.15 CET. For further information, please contact: Patrik Lundström, CEO: +46 (0) 46 10 16 00 or +46 (0) 703 27 37 38 Björn Segerblom, Chairman of the Board:  + 46 (0) 46-10 16 00 or +46 (0) 852 6071 2250 About IMB-CNM The Barcelona Microelectronics Institute (IMB) is the Barcelona location of the National Microelectronics Center (CNM). It belongs to the Spanish Research Council (Consejo Superior de Investigaciones Científicas - CSIC) since its foundation in 1985, together with the institutes in Madrid, (IMM-CSIC) and Seville (IMSE-CSIC). The main activities of IMB-CNM is basic and applied research and development, education and training in micro and nanotechnologies, components and systems. Its mission is to improve the knowledge and to contribute to the implementation of solutions based in these technologies in new products, for solving societal challenges. About Obducat AB (publ) Obducat AB (publ) is an innovative developer and supplier of technologies, products and processes used for the production and replication of advanced micro and nano structures. Obducat’s products and services serve the demands of companies within the LED, OLED, semiconductor, displays, biomedical and MEMS industries. Obducat’s technologies include nano imprint technology, coating technology and wet processing technology. Obducat has offices in Sweden, Germany and China and the headquarter is located in Lund, Sweden. Obducat’s class B shares and preferential class B shares are publicly traded on the Swedish NGM Equity stock exchange. Read more at www.obducat.com.

ExpreS2ion Biotech Holding AB: Publication of financial report for January – March 2018

Q1 (2018-01-01 – 2018-03-31) · Group turnover amounted to 2 278 (3 614) KSEK. · Result after financial items amounted to -3 451 (-1 218) KSEK. · Net income amounted to -3 217 (-1 109) KSEK. · Net income per share* amounted to -0,32 (-0,13) SEK. · Cash flow from operating activities amounted to -2 996 (-3 987) KSEK. · Equity ratio** amounted to 64,2 (52,5) %. · Cash and cash equivalents amounted to 17 775 (2 460) KSEK * The group’s net income per share: the net income for the period divided by 10 135 035, the average number of shares for the period. The total number of shares in ExpreS2ion Biotech Holding AB was 12 002 015 shares per 2018-03-31. ** Equity ratio: Shareholder’s equity divided by total capital. Significant events during the first quarter 2018 · On January 16, 2018, ExpreS2ion Biotech Holding AB announced that the Board decided, pursuant to the authorisation granted by an Extraordinary General Meeting, to carry out a preferential rights issue with the aim to accelerate the Company's development. The preferential rights issue comprises a maximum of 2 400 403 shares with a subscription price of 8.00 SEK per share. Upon full subscription of the rights issue, ExpreS2ion will raise approximately MSEK 19.2 before issue expenses. The proceeds from the preferential rights issue are expected to finance ExpreS2ion’s possibilities to pursue additional projects regarding vaccines and candidate drugs that the Company regularly encounter on the market. In addition to this, the preferential rights issue will provide resources to create more value in the joint venture AdaptVac and its development projects. Finally, the preferential rights issue will finance further development of the Company’s platform with new products that will strengthen the Company's position in new market segments and generate new clients, thereby increasing the Company's short-term earnings as well as long-term possibilities. · On February 1, 2018, ExpreS2ion Biotech Holding AB held an extraordinary general meeting. The report is available on the Company’s website (www.expres2ionbio.com). · On March 2, ExpreS2ion Biotech Holding AB announced the result of the Company’s preferential share issue. The rights issue was subscribed to approximately SEK 30.3 million, corresponding to a subscription rate of approximately 158 percent. Through the rights issue, a total of 2 400 403 shares are issued and ExpreS2ion is provided approximately SEK 19.2 million before issuing costs. Significant event after the end of the period · On April 20, ExpreS2ion Biotech Holding AB announced that the subsidiary’s U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. It was also stated that IBT is planning to launch approximately five products for research purposes annually, and that the collaboration is expected to generate annual revenues of up to 1 MSEK to ExpreS2ion, when fully implemented. CEO Steen Klysner comments “In the first quarter of 2018, ExpreS2ion was able to build further upon the fast-paced development and progress of the Company since our listing on Nasdaq First North in 2016, including a very strong 2017. All in all, we are indeed continuing to develop the Company at full speed towards the goals presented in connection with the recent rights issue, and I look forward to fully realise them in due time.”  Financial calendar Annual General Meeting, 2018 2018-05-24Half year Report, 2018 2018-08-24Interim report Q3, 2018 2018-11-22Year-end report, 2018 2019-02-28 Certified Adviser Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion Biotech Holding AB.

Crown Energy AB: Interim report, January-March 2018

KEY EVENTS DURING THE QUARTER · Crown Energy’s financials have been influenced substantially by the devaluation in Angola that occurred during the quarter. The Central Bank of Angola released the pegging of the Angolan Kwanza against the US dollar, which resulted in a devaluation effect of approximately 22.5 percent during the quarter. · On 26 February 2018 the Company announced that the extension to move into the second period of the Exploration Right over Block 2B offshore South Africa was granted by the South African authorities. The exploration rights period now runs until February 2020 and includes drilling of a well on the licence. Crown Energy holds a 10 per cent equity position in licence Block 2B in South Africa. · On March 8 2018, Crown Energy announced that it had entered into an Areas of Mutual Interest Co-operation agreement with the Italian Engineering firm Proger S.p.A. (“Proger”). By this agreement Crown Energy continues to strengthen its Asset Development and Management business area. Crown Energy and Proger have agreed to work together to seek and identify commercial projects, where each company's competencies complement each other. Both companies agreed to represent each other through their respective office net- works, thus enhancing their presence in the international market. CEO Statement DEAR SHAREHOLDERS AND INVESTORS,              Following Crown Energy’s substantial transaction acquiring ESI Group in 2017, we have now entered into 2018 and can publish the first quarter report. Our financials have been influenced substantially by the devaluation in Angola that occurred during the quarter. The Central Bank of Angola released the pegging of the Angolan Kwanza against the US dollar, which resulted in a devaluation effect of approximately 22.5 percent during the quarter. A positive thing however is that Crown Energy’s underlying operating business in Angola has done better during the first quarter. The revenues, in local currency, increased compared to the same period last year as well as against the previous quarter. Revenues increased by 1.7 percent compared to the fourth quarter 2017 and by 7.2 percent compared to the first quarter 2017. Converted to our reporting currency, the Swedish Krona, we however see how the devaluation has had a negative effect on the revenues. However, due to other currency conversions, we are reporting a significantly higher before tax profit compared to previous periods. Crown Energy reports revenues of SEK 20.6 million (27.8) for the first quarter 2018. The rental incomes amounted to SEK 13.0 million (18.1), and our service incomes to SEK 7.6 million (9.6). The profit before tax (EBIT) amounted to SEK 44.3 million (8.1) and was affected by the substantial fluctuations in currencies, which is mainly recorded in the financial items. Our comparison figures must be seen in the light of last year’s ESI Group reverse take-over and therefore the “old” Crown Energy group’s costs are not reported during the first six months 2017. In the longer run, the effects of the devaluation and the ongoing inflation in Angola, are counteracted by the fact that Crown Energy has a built-in index to the US dollar in almost half of our client contracts. In order to mitigate the currency risks, our subsidiary in Angola also signed two hedge agreements in October 2017. One of the instruments is hedging against the US dollar and the other one is an interest bearing instrument running with 22 percent interest. The situation in Angola definitely reinforces our strategy going forward – to spread our Asset development concept to new markets, to continue to negotiate our client contracts in dollar or Euro as well as sign new rental and service contracts in existing properties. The increasing oil price is also positive for the underlying economy in Angola, and will likely cool off the inflation in the country. It is the Company’s absolute determination and goal to secure business development and growth going forward. New projects within the Asset Development and Management business and also to capitalise on the oil and gas assets in the Energy business are our highest priorities. The company sees that the effects of currency changes in the Angolan economy, further increase the value for us to establish cash flow generating activities in new markets to diversify and hedge currency risks. We also see an improved situation within the oil industry due to the positive oil price development. Our oil and gas projects have generally developed very well until today. An increase in oil prices may eventually be very positive for Crown Energy, as investments in the energy sector in general, and in the oil and gas industry specifically, are expected to speed up going forward. Investments in the oil industry has had a substantial dip in recent years. This usually creates a need for new investments in the industry and together with a steady oil price at higher levels this can definitely trigger such investments. It is impossible to predict exactly when such investments will begin to increase. But we can already read about several oil and gas fields that are put into operation and general investments have been announced. There might be a need for a longer period of higher oil price in order for the effect to be further noticeable in the market. But we believe that it will affect our assets positively in both our business areas. BUSINESS DECISIONS THAT AFFECTED THE COMPANY’S PERFORMANCE Since the acquisition of ESI Group in 2017 much work has been invested to implement the acquired business into Crown Energy. And more importantly, a massive amount of efforts has been invested in order to establish our asset development concept on new markets, mainly through new customer sales. That is something that we look forward to see materialise into a firm business growth for Crown Energy. OUTLOOK The Company now continues its progress towards a larger and even more stable foundation to stand on. We will make use of our prominent contacts in the oil industry to develop our business on both existing and new markets, and future cash flows should guarantee faster development of the Company’s existing assets. Capital and organisation will be further adapted as part of the exciting continuation of Crown Energy's development work. We look forward to continuing our efforts to capitalise on our assets, thus continuing to create value for you, our shareholders. Andreas Forssell, CEO Crown Energy This information is information that Crown Energy AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.30 AM CET on 17 May 2018.

BONESUPPORT creates its own US Commercial Platform

Lund, Sweden, 08.45 CET, 17 May 2018 – BONESUPPORT HOLDING AB (publ) announces today that the current distribution agreement has been terminated and will be replaced by a network of independent distributors and its own commercial organization. This will allow BONESUPPORT to increase its market penetration while creating a stronger platform for current products and future launches in the US market. “Taking control of our commercial platform in the US is crucial to the execution of our strategy to become a leading global orthobiologics company. We will be able to create a more direct relation with the US customers while better capitalizing the potential of our highly differentiated products, particularly CERAMENT G, which we hope will take to the market in 2021”, says Emil Billbäck, CEO of BONESUPPORT. The company intends to create the optimal US commercial platform by: ·  Building its own network of independent distributors driving the sales of the BONESUPPORT’s products, to a broad range of orthopedic indications. ·  Extend the product offering based on new formulations of CERAMENT as well as synergistic bone graft substitute products. ·  Increase the own commercial organization from 12 to 23 persons. BONESUPPORT will start selling direct on October 20th 2018. “CERAMENT G will be a highly innovative product – the first of its kind in the US market – the recruitment of the FORTIFY IDE study, which will provide data for the PMA application of CERAMENT G in 2020, is running according to plan. Expanding our commercial footprint, establishing direct access with our customers, and bolstering our product offering in the US will allow us to build a strong and increasing foundation in the world’s largest market for bone graft substitutes.”, comments Patrick O’Donnell, Executive Vice President of Commercial Operations, North America. The Company expects that this decided change in market commercialization eventually will generate higher sales volumes in the US. In the short term, the turnover will be less in the US. This could also lead to that the 2020 targets will be achieved later than previously communicated. We will present updated objectives during Q3 2018 after the initiated strategic review is completed.  Conference Call/Webcast Details   The Company will host a conference call and an online presentation at 09:30 am CET on Thursday 17 May. The dial-in numbers for the conference call are: UK: +44 20 3008 9808SE: +46 85 063 95 49US: +1 85 5831 5946  Webcast  The presentation will also be webcast and can be accessed from the following web address: https://tv.streamfabriken.com/2018-05-17-bonesupport-pressconference  Hosts: Emil Billbäck, CEO and Björn Westberg, CFO

Delays and uncertainty in AJ Group transaction results in liquidity issues

Following Invuo Technologies AB (“Invuo”) market communication on 30 April, 2018 regarding the status of the expected investment by AJ Group Holdings Ltd (“AJ Group”), to purchase 20m new shares, and loans in Seamless Distribution Systems AB held by Invuo (representing a total investment of 52 mSek), we regret to inform the market that further delays have occurred in the transfer of funds. Management and the Board consider that it is now a high risk that sufficient funds from the AJ Group investment to continue operations might not be available to Invuo in a reasonable timeframe. Additionally, information from AJ Group recently received by Invuo, indicates that AJ Group may seek to make the undertaking agreement, executed in March 2018, conditional of new requirements, not part of the already executed undertaking. This new information has forced Management and the Board to reassess the probability of actually receiving funds according to the terms set forth in the undertaking agreement. Primarily as a result of the delays related to the expected investment by AJ Group, Invuo’s liquidity position has become critical. Management and the Board will utilise all available avenues to seek alternative funding, in order to provide liquidity to allow operations to continue. For further information, please contact:John Longhurst, CEO, john.longhurst@invuo.com, +46 8 564 878 00 This information is such that Invuo Technologies AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 08:50 on May 17, 2018. About InvuoSince 2001 Invuo has been providing its proprietary solutions and systems for mobile phone transactions. Invuo operates in two main business areas; mobile phone payment solutions provided through the brand MeaWallet™, and distribution of e-products. www.invuo.com 

Itiviti and ULLINK partner with SEB for Systematic Internaliser solution

Stockholm, Sweden, May 17, 2018 – Itiviti and ULLINK, the recently merged market-leading global provider of multi-asset trading technology and financial infrastructure, today announced that it was selected by the leading Nordic financial services group SEB to implement its new solution for client quote management and systematic internalisation. The new solution allows a broker acting as a Systematic Internaliser (SI) to comply with MiFID II regulations addressing quote management, pre-trade transparency, reporting and best execution. Since the introduction of MiFID II in 2018, brokers acting as liquidity providers in MiFID instruments must comply with new rules addressing client Request For Quote (RFQ) management, quote publication and reporting. ULLINK’s UL QUOTE solution – a modular extension to ULLINK’s Order Management System (OMS) – enables brokers to receive cross-asset class RFQs and direct them to the most appropriate source of liquidity, including internal options. Itiviti’s Systematic Internaliser provides high performance and scalable auto quoting functionality and efficient multi-asset class internalisation, with support for order and RFQ driven interaction with external systems. Pre-trade and post-trade quote publication is automated, as is capture of relevant data for record keeping and reporting. “We have worked closely with ULLINK and Itiviti to ensure the new Systematic Internalisation solution meets our business objectives as well as compliance requirements,” says Christer Wennerberg, Product Manager Equities, SEB. “ULLINK’s modular architecture allows us to easily integrate the new extension with our existing ULLINK OMS and connectivity platform, as well as with Itiviti’s Systematic Internaliser to extend the services we can offer our customers. Our decision to register as an SI under MiFID II was greatly facilitated by the timely availability of the combined turnkey solution.” SEB has longstanding relationships with ULLINK and Itiviti. The bank has used ULLINK to support its equity trading activity since 2004, leveraging solutions for client and market connectivity as well as order and execution management across sales and dealing desks. Additionally, SEB uses the Tbricks by Itiviti trading platform to support equity cash and derivatives trading, as well as its market making operations. “The changes in market structure due to MiFID II presents challenges as well as opportunities for brokers,” says Richard Bentley, Chief Product Officer, ULLINK. “SEB has embraced these changes to innovate solutions and realize new business opportunities. UL QUOTE is the latest output from a long, successful collaboration between ULLINK and SEB that ensures we continue to build products which help our clients achieve their business goals.” “Looking at SEB’s approach to Systematic Internalisation, it is clear that where others may see challenges, they are addressing market opportunities,” adds Jonas Lindqvist, Strategic Research, Itiviti. “Working with SEB, we have been able to provide an internal venue that is not only MiFID II compliant, but also lets SEB extend it with their own logic.” For further information, please contact:Christine Blinke, Chief Marketing Officer, Itiviti, Tel. +46 739 01 02 01, christine.blinke@itiviti.com    Mireille Adebiyi, Marketing & Communications Director, ULLINK, Tel. +33 1 49 95 30 00, mireille.adebiyi@ullink.com  About Itiviti and ULLINKItiviti and ULLINK have formed a market-leading global provider of multi-asset trading technology and financial infrastructure solutions for buy-side and sell-side market participants, including NYFIX, one of the industry’s largest FIX-based trading communities. Serving more than 1,900 clients worldwide, we provide consistent, reliable access to the most up-to-date and innovative order routing, connectivity and trading solutions available. Top-tier trading firms, banks, brokers, exchanges and institutional investors rely on our technology, solutions and expertise to streamline their daily operations, connect to their desired markets, and trade when and where they want. All while being able to comply with global regulation. With global offices in 18 locations covering all major financial centers, the merger of Itiviti and ULLINK in March 2018 creates a full service technology and infrastructure provider, covering all asset classes, geographies and regulatory landscapes. For more information, please visit www.itiviti.com or www.ullink.com. Itiviti and ULLINK are owned by Nordic Capital Fund VII.  

New study results presented at ASCO supports DiviTum® for monitoring advanced breast cancer treatment

DiviTum® measures the activity of serum thymidine kinase (TK) activity which plays a critical role in DNA synthesis and cell proliferation. The study found that serum TK is a circulating prognostic and monitoring marker in patients with advanced breast cancer treated with hormonal therapy. By evaluating levels of TK during treatment DiviTum® can provide important information for treating physicians. Patients resistant to on-going hormonal therapies can be identified, enabling alternative treatment options. The ASCO (American Society of Clinical Oncology) annual meeting taking place June 1-5 in Chicago is the largest scientific cancer congress in the world (40 thousand participants in 2017). “Endocrine therapy is the treatment of choice for patients with metastatic breast cancer expressing hormone receptors; however, as clinicians, we currently do not have tools to early identify those patients who will do good with endocrine therapy alone or may need additional treatment. The results from our work with DiviTum are exciting and confirm in a larger number of patients our previous observation that this assay may indeed help clinicians in this hard task. DiviTum will certainly become a very useful tool for the development of innovative clinical trials in this field, and ultimately for clinical practice”. – says Dr Luca Malorni, MD, PhD, Prato Hospital, Italy. “These results reinforce what we have seen in previous studies, proving that DiviTum® can provide clinically relevant information highly beneficial for women with advanced breast cancer on hormonal therapy.” – says Anders Rylander, CEO Biovica and continues,”We are convinced that bringing products like DiviTum® to the market will contribute to bringing the best possible treatment for cancer patients.” Malorni L et al, ASCO Annual Meeting 2018; abstract #12031 http://abstracts.asco.org/214/AbstView_214_219453.html

Global Gaming names Lars Kollind as Head of B2B

With his extensive industry knowledge and long track record in the iGaming business, Lars Kollind is the perfect profile to spearhead the organisation’s future B2B offering with a view to bolstering Global Gaming’s growth objectives and its ambitions to emerge as a leading player in the iGaming space. Kollind, who will be based at Global Gaming’s Malta Office in Sliema, previously enjoyed a successful career as Sales Director for B2B at Aspire Global and joins during a new and exciting chapter in Global Gaming’s history. Some of the company’s successful brands such as Netticasino and Vikingslots operate on the Aspire Global platform, meaning that Kollind has already gained a thorough understanding of Global Gaming’s offering.“I could not think of a better time to join Global Gaming. As the organisation seeks to grow, it seems natural to add a new vertical in the B2B product.”, Kollind says, “Drawing from the success story that is NinjaCasino.com, our goal is to keep on focussing on innovation and enhancing the user experience. As a consequence, our B2B product focus will be on differentiation in the form of experience customisation, leveraging my experience in the field, as we seek to attract high-profile partners and white label casinos”. His appointment closely follows a recent wave of key appointments in Global Gaming’s Product Team, including several ex- GiG talents. "Lars joins us to take complete business ownership and development of our B2B offering. His experience and knowledge of the B2B marketplace is invaluable as we continue to put in place the foundations for the continued growth of Global Gaming.", says CPO and MD Malta Mark Wadsworth. For further information Mark Wadsworth, Chief Product Officer and MD Malta, Global Gamingmark.wadsworth@globalgaming.com About Global Gaming Global Gaming is a challenger in the iGaming industry, delivering innovative and safe gaming services and operating a number of successful casino brands . Its flagship, Ninja Casino , builds on a revolutionary technology allowing players to enjoy a safe and seamless online casino experience without the hassle of a lengthy registration process.

”Passage” has arrived at its home port!

Bertil Vallien, glass artist Bertil Vallien’s focus on looking inward is achieved in myriad ways, one of which is his unique glassmaking technique. A leader in the Swedish glass industry for more than 40 years, Vallien formulated his own method for casting glass in sand that creates depth and radiance in the material. Artworks are driven not by their final appearance—although their visual impact is stunning—but rather by their content. Vallien’s preparatory sketches are carefully considered blueprints of both the external form and the inner details. Layers—both physical and psychological—are created through a multistep process. Surface textures result from the imprint of objects placed on the walls of the mold, which are also dusted with powdered metal oxides to release color. As the molten glass is poured into the mold, Vallien incorporates a variety of objects from sheet metal and glass threads, to figures and other colored forms. Once the glass cools, the suspended animation reveals itself in full glory. Light reflects off the brilliant surfaces and assorted angles of the perimeter, but more dramatically it emanates from within.   Vallien's expression in art glassVallien has said that “knowing the exact moment at which to capture a shift of light or expression and wrench the secret from the glass is what it is all about.” Just as his technical approach unearths internal “secrets,” so his visual motifs are explorations of the subconscious. The artist is motivated by various things—from stories he hears on the news, to people he has met, to his religious upbringing and questions about faith, to wars both historical and contemporary. Despite these concrete inspirations, the work is not meant to pose facile questions with prescribed answers. Vallien’s art embraces this idea, transforming the events and experiences that inspire him into universal archetypes and symbols, upon which viewers layer their own perspectives. A shifting “truth” is created when two spirits—that of the artist and that of the viewer—coalesce. Bertil is internationally renowned, holds several design and art awards, and his work is represented in the most prestigious museums around the world. Thus, we are honored to unveil Passage, perhaps Bertil Vallien's most awe-inspiring and majestic masterwork.- Donna Davies, Vice President, Art Group of Urban Expositions Passage embodies an extraordinary artistic partnership between Bertil Vallien, one of the world's leading artists, and Kosta Boda, Sweden's most storied glassworks. Hawk Galleries feels privileged to unveil the crown jewel of these two titans' 53-year collaboration at one of America's leading art fairs, SOFA Chicago 2016.- Tom Hawk, Jr. Director, Hawk Galleries

Announcement from Crown Energy’s annual general meeting

Adoption of the income statement and the balance sheet The AGM resolved to adopt the income statement and the balance sheet in the Company and the consolidated income statement and the consolidated balance sheet. Allocation of profit The AGM resolved that no dividend would be paid to the shareholders and that the previously accrued profits, including the share premium account and year result, in total SEK 1,612,512,278, would be carried forward. Discharge from liability The board of directors and the CEO were discharged from liability for the financial year 2017. Election of the board of directors, auditor and remuneration The AGM resolved that the board of directors shall comprise four directors and no deputy directors. The AGM resolved that the number of auditors shall be one registered audit firm. It was further resolved that the remuneration to each of the non-employed directors, shall comprise an amount of SEK 150,000 to the chairman of the board and to an amount of SEK 75,000 to the other directors, in total SEK 300,000, and remuneration to the auditor shall be paid in accordance with approved invoices. The remuneration to the board of directors remain unchanged from the previous year. Jean Benaim, Yoav Ben Eli, Alan Simonian and Pierre-Emmanuel Weil were re-elected as directors of the board. Pierre-Emmanuel Weil was re-elected as the chairman of the board. Öhrlings PricewaterhouseCoopers AB was re-elected as the Company auditor. Öhrlings PricewaterhouseCoopers AB has announced that Bo Lagerström remains as main responsible auditor. Guidelines for remuneration to the senior executives The AGM resolved, in accordance with the board of directors proposal, to adopt, in principle, the same guidelines adopted at the AGM 2017. Change of the articles of association The AGM resolved, in accordance with the board of directors’ proposal regarding a change of the articles of association with respect to removal of the C shares, whereby they no longer can be issued by the Company. All clauses relating to the C shares were adjusted in order to enable the removal of the C share. In view of the above it was also resolved that the current ordinary shares shall have one vote each. It was also resolved to change the limits of the share capital from a minimum of SEK 4,277,264 and a maximum of SEK 17,109,056 to a minimum of SEK 14,000,000 and a maximum of SEK 56,000,000. It was further resolved to change the limits for the number of shares from a minimum of 145,487,301 and a maximum of 581,949,204 to a minimum of 477,000,000 and a maximum of 1,908,000,000 This information is information that Crown Energy AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 13.30 AM CET on 17 May 2018.

Vator Securities acted as Sole Bookrunner and Advisor in connection with Ascelia Pharmas Pre-IPO share issue

Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products with potential to significantly improve survival in cancer patients. The lead asset Mangoral® is a novel MR imaging (MRI) drug, which is being developed for detection of liver metastases in patients with severely impaired kidney function who are at risk of serious side effects if given any of the current imaging drugs on the market. Today, these patients have no safe and effective imaging drug to improve the detection of liver metastases. Mangoral® will fill the gap for this patient segment and potentially improve their survival rate. The market size for this patient segment is estimated to USD 350-500 million. Mangoral® has Orphan Drug Designation from FDA and is ready for Phase III, with estimated completion in H1-2021. The second product candidate Oncoral is a novel chemotherapy tablet for the treatment of gastric cancer – a market estimated at USD 3.5 billion in 2020. Oncoral is currently in Phase I, with estimated completion in 2018. Ascelia Pharma is backed by a wide and well-renowned group of shareholders, Key Opinion Leaders and advisors. Ascelia Pharma is preparing for a main market listing on Nasdaq Stockholm in Q1 2019. The proceeds from the equity issuance will primarily be used to finalize preparations for the Mangoral® Phase III clinical study as well as complete the ongoing Oncoral Phase I study.

Healthcare IT business Trialbee pursues strategic expansion through new talent and investment

Trialbee mobilizes and prepares for strategic expansion through the addition of new investments. Trialbee is a Swedish clinical trial technology company providing smart patient matching and engagement services to accelerate drug development for pharmaceutical companies and contract research organizations (CROs) around the world. Investors include Stiftelsen Industrifonden, Briban AB, Birgerson Invest LLC and Ulf Wiinberg Consult & Invest AB, Anders Tullgren, Daniel Spasic and Newton Aguiar. “We increased our investment in Trialbee because we believe that the company’s prospects for growth are very bright,” said Patrik Sobocki from Industrifonden, one of the largest venture capital firms in the Nordic region. “There is a huge need for greater digitalization in clinical research, and the unique end-to-end technology platform that Trialbee offers is unmatched by anything else we’ve seen in the market.” As a part of Trialbee’s plans for expansion in the US market, the company has recruited two new executive leadership roles. Lollo Eriksson has been appointed CEO, succeeding founder Tobias Folkesson, who is assuming the role of Strategic Technology Advisor. Robert Molander has joined as the global Senior VP of Marketing. Eriksson and Molander bring extensive clinical and commercial life science experience to the company. The board has been further strengthened by the addition of Anders Tullgren (as chairman), Newton Aguiar and Daniel Spasic (board members). Tullgren brings pharmaceutical executive leadership experience, Aguiar private equity healthcare experience while Spasic is the founder of the global CRO TFS. “Trialbee is entering a new growth phase and bringing on professionals with extensive life science industry experience is a natural part of that transition,” said Anders Tullgren, chairman of Trialbee. “I am thrilled to be guiding such a diverse and talented team – it’s a company where people with executive experience in pharma and clinical research are now working seamlessly with best-in-class programmers and interaction designers.” The diversity of perspectives across Trialbee’s executive leadership team and the board is seen as a strategic asset in contributing towards the company’s continued expansion.

Report from the Annual General Meeting in Nexam Chemical Holding (publ)

Adoption of accounts and distribution of the company’s results   The AGM resolved to adopt the presented profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and consolidated balance sheet. The AGM also resolved to distribute the Company’s results in accordance with the Board of Directors’ proposal in the Annual Report meaning that no dividends are paid and that unappropriated earnings are carried forward to a new account. Discharge from liability   The AGM resolved to discharge the Board members and the Chief Executive Officer from liability for the financial year 2017. Remuneration   The AGM resolved that remuneration for the Board shall be paid with a total of SEK 690,000, of which SEK 190,000 shall be paid to the Chairman and SEK 125,000 to every other Board member. The AGM also resolved that remuneration for the auditor shall be paid according to approved invoice and customary norms. The Board of Directors  Lennart Holm, Cecilia Jinert Johansson, Daniel Röme and Per-Ewe Wendel were re-elected as Board members. Jonna Opitz was elected as new Board member. Furthermore, Lennart Holm was re-elected as Chairman of the Board. Auditor   The AGM resolved to re-elect MAZARS SET Revisionsbyrå AB as the auditor until the end of the next AGM. MAZARS SET Revisionsbyrå AB has informed that Bengt Ekenberg will continue to be appointed as the lead auditor.   Instruction for the Nomination Committee   The AGM resolved that the work of the Nomination Committee before the AGM 2019 shall be conducted in accordance with the proposal, see item 12 in the notice to the AGM which was published on April 17, 2018. The Nomination Committee shall consist of three members representing the three largest shareholders as per June 30, 2018. The Chairman of the Nomination Committee shall be the member appointed by the largest shareholder in terms of the number of votes, unless the members of the Nomination Committee agree differently. Remuneration will not be paid to the members of the Nomination Committee. Information on the members of the Nomination Committee and the shareholders they represent shall be published through a press release no later than six months prior to the next AGM. Remuneration Policy   The AGM resolved on a Remuneration Policy for senior executives in accordance with the proposal, see item 13 in the notice to the AGM which was published on April 17, 2018. The remuneration for the CEO and other senior executives may consist of fixed salary, variable remuneration, pension, other benefits and share-based incentive programs. The guidelines means i.e. that the CEO and other senior executives will be offered a fixed salary on market terms. The remuneration for the CEO and other senior executives shall be based on factors such as work tasks, expertise, experience, position and performance. The variable remuneration shall be conditional in relation to variable remuneration targets and shall for the CEO not exceed 100 per cent of fixed salary and shall not exceed 50 per cent of fixed salary for other senior executives. The variable remuneration for 2018 can amount to – if all targets are met in full – at the highest approximately SEK 6.1 million (including social charges). The guidelines shall be applied on new agreements, or changes in existing agreements reached with senior executives after the guidelines have been adopted, and until new or revised guidelines have been determined. Authorization for the Board of Directors to resolve on new issues of shares   The AGM resolved to authorize the Board of Directors, on one or several occasions until the next AGM, with or without deviation from the shareholders’ preferential rights, to resolve on new issues of shares. Issues may be made with or without provisions regarding contribution in kind, set-off or other conditions. The number of shares that may be issued may not exceed a total of 7,502,113 shares. The dilution may, upon full exercise of the authorization, amount to a maximum of approximately 10 per cent. The purpose of the authorization is to enable to raise working capital, to enable to execute and finance acquisitions and to enable new issues to industrial partners within the framework of partnerships and alliances. To the extent the authorization is used for new issues with deviation from the shareholders’ preferential rights, the issue price shall be on market terms. The resolution was adopted in accordance with the proposal, see item 14 in the notice to the AGM which was published on April 17, 2018. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.   For further information please contact:   Lennart Holm, Chairman of the Board, +46-706 30 85 62, lennart.holm@nexamchemical.com Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com ___________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com. The company´s Certified Adviser is FNCA Sweden AB.

Distribution and listing of Epiroc AB

Nasdaq Stockholm’s Listing Committee has resolved to admit Epiroc’s shares of series A and shares of series B to trading on Nasdaq Stockholm subject to customary conditions, such as the Swedish Financial Supervisory Authority's approval of the prospectus. All shares in the wholly-owned subsidiary Epiroc AB will be distributed to Atlas Copco AB’s shareholders in proportion 1:1. One share in Atlas Copco AB will entitle to one share in Epiroc AB. Holders of a series A share in Atlas Copco AB will receive one series A share in Epiroc AB and holders of a series B share in Atlas Copco AB will receive one series B share in Epiroc AB. Apart from being registered as a shareholder of Atlas Copco AB on the record date for distribution, no further actions are required. The last day for trading in shares of Atlas Copco including the right to receive shares in Epiroc is June 12, 2018. As of June 13, 2018 the Atlas Copco share will be traded without the right to receive shares in Epiroc. The first day of trading in Epiroc is expected to be June 18, 2018. Epiroc’s shares of series A will be traded under the ticker EPI A with the ISIN code SE0011166933 and shares of series B will be traded under the ticker EPI B with the ISIN code SE0011166941. The prospectus for admission of trading of Epiroc’s shares is expected to be published on May 25, 2018. The prospectus will be available on Atlas Copco’s  and Epiroc’s  websites. Indicative timetable:May 25, 2018: The prospectus will be available June 12, 2018: The last day for trading in shares of Atlas Copco including the right to receive shares in EpirocJune 13, 2018: Atlas Copco will be traded without the right to receive shares in EpirocJune 14, 2018: Record date for the distribution of shares in EpirocJune 18, 2018: First day of trading in Epiroc

Triton to sell Aventics to Emerson

Laatzen (Germany), 17 May 2018 – Triton has initiated the next step to ensure a prosperous and sustainable future for Aventics by announcing its intention to sell the company to Emerson. There has been an agreement on terms with Emerson and the regulatory approval process is now underway. Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial, and residential markets. The Emerson Automation Solutions business helps process, hybrid, and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. "We would like to thank the management team, the employees and all other stakeholders for their contributions to Aventics successful development during Tritons ownership. Triton has been the owner of Aventics for more than four years and we view this as an appropriate time for a long-term industrial owner to continue the development of Aventics. Emerson is an ideal partner for Aventics going forward with an ideal cultural fit. This partnership will open new opportunities for both companies" says Peder Prahl, Director of the General Partner to the Triton fund. The transaction is expected to close in the third quarter of 2018 subject to regulatory approvals, finalization of necessary consultations and other customary closing conditions. About AventicsAventics is one of the world’s leading manufacturers of pneumatic components and systems. The pneumatic engineering company provides products and services for industrial automation, as well as the food, packaging, medical, and energy technology industries. The company also develops solutions for the commercial vehicles, marine, and railway technology sectors. By integrating electronics, the use of state-of-the-art materials, and focusing on machine safety and the Internet of Things (I4.0), Aventics is a pioneer in applied and environmentally-friendly solutions. Aventics is preparing for the future by expanding its approach to digitalization. With around 150 years of expertise in pneumatics, Aventics employs over 2,000 associates worldwide. From production sites in Germany, France, Hungary, the USA, and China, Aventics markets its products in over 100 countries through direct sales and sales partners. The Aventics Group has received multiple certifications, including ISO 9001 and ISO/TS 16949 for quality, ISO 50001 for energy management, and ISO 14001 for environmental management. Further information is available at www.aventics.com. About EmersonEmerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial, and residential markets. Our Emerson Automation Solutions business helps process, hybrid, and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Emerson Commercial & Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency, and create sustainable infrastructure. For more information visit www.Emerson.com. About TritonThe Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors. Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 37 companies currently in Triton's portfolio have combined sales of around €14.3 billion and around 91,000 employees. The Triton funds are advised by dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey. For further information: www.triton-partners.com Press Contacts: TritonMarcus Brans                                                 Phone: +49 69 921 02204Mail: brans@triton-partners.com   EMERSONDerek ThomasPhone: +1 972 548 3140Mail: DerekThomas@Emerson.com AVENTICSPeter SaffePhone: +49 511 2136 137Mail: peter.saffe@aventics.com Meike Müller-WiegandPhone: +49 511 2136 862Mail: meike.mueller-wiegand@aventics.com

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

· The presented annual report was adopted and the members of the Board of Directors and the CEO were discharged from liability in respect of the financial year 2017. · It was resolved to carry forward the loss for the year in accordance with the Board of Directors’ proposal. · The proposed remunerations to the Board of Directors, its committees and the Company’s auditor were approved. · Jonas Brambeck, Cecilia Daun Wennborg, Jarl Ulf Jungnelius, Per Samuelsson and Olof Tydén were re-elected as board members. Brian Stuglik and Per Wold-Olsen were elected as new board members. Per Wold-Olsen was also elected as Chairman of the Board of Directors. · It was resolved to adopt the proposed guidelines for remuneration to the senior management. · It was resolved to adopt the proposed principles for the establishment of the Nomination Committee and instructions regarding its work. · It was resolved, in accordance with the Board of Directors’ proposal, to introduce a long term incentive program for members of the senior management and key persons (including employees and consultants) in the Company (“Co-worker LTIP 2018”). The participants will be granted options which after three years will entitle to the acquisition of shares in the Company at a pre-determined exercise price corresponding to the volume weighted average price of the Company’s share for the five trading days preceding the granting date of each option. Each option entitles to the acquisition of one share in the Company and a total of not more than 440,025 options will be granted. It was further resolved, in accordance with the Board of Directors’ proposal, to issue not more than 440,025 warrants in order to ensure delivery of shares and for hedging of social security costs under Co-worker LTIP 2018. It was further resolved, in accordance with the Board of Directors’ proposal, that warrants that have been issued by Oncopeptides under Co-worker LTIP 2017 for the purpose of hedging Oncopeptides’ social security costs under Co-worker LTIP 2017 can be used under Co-worker LTIP 2018 to cover social security costs under Co-worker LTIP 2018. · It was resolved, in accordance with the Nomination Committee’s proposal, to introduce a long term performance based incentive program for certain members of the Board of Directors (“Board LTIP 2018”). The program is share based and intended for main owner independent members of the Board of Directors. The program comprises a total of not more than 55,000 share awards and the number of share awards that shall be awarded to each participant shall correspond to a certain amount (SEK 1,350,000 to the Chairman and SEK 540,000 to each of the other main owner independent members of the Board of Directors) divided by the volume weighted average price of the Company’s share on Nasdaq Stockholm for the 30 trading days preceding the Annual General Meeting. The share awards are subject to performance vesting based on the development of the price of the Company’s share over the period from the date of the Annual General Meeting up until the annual general meeting 2021. Each vested share award entitles the holder to receive one share in the Company without any compensation being payable provided that the holder is still a Board member of the Company at the relevant times of vesting. It was further resolved, in accordance with the Nomination Committee’s proposal, to issue not more than 55 000 warrants in order to ensure delivery of shares under Board LTIP 2018. · It was resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, until the next Annual General Meeting, on one or more occasions, decide upon issuances of new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise on terms. The number of shares issued under the authorisation, or the number of shares created in connection with exercise of warrants or conversion of convertibles, may not correspond to a dilution of more than 20 per cent of the total number of shares outstanding at the Annual General Meeting’s resolution on the proposed authorization, after full exercise of the authorization. For further information Jakob Lindberg, CEO, Oncopeptides ABE-mail: jakob.lindberg@oncopeptides.seTelephone: +46 (0)8 615 20 40 Rein Piir, Head of Investor Relations, Oncopeptides ABE-mail: rein.piir@oncopeptides.seTelephone: +46 (0)70 853 72 92 About Oncopeptides Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. The company focus on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxic (PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from ­treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.   For more information visit www.oncopeptides.se. The above information was released for public disclosure on 17 May, 2018 at 18.30 (CET).


The Annual General Meeting adopted the income statement and balance sheet, the consolidated income statement and the consolidated balance sheet for the year 2017. The Annual General Meeting resolved that no dividend be paid to the shareholders for the year 2017. Instead of a dividend, the Annual General Meeting resolved on a share redemption program as set out below.   Directors The Annual General Meeting resolved to re-elect the Directors Christel Kinning, Fredrik Lövstedt, Mats H Nilsson and Heiner Olbrich, and to elect Göran Carlson and Alessandra Cama as new Directors. Martin Bjäringer and Lotta de Camps have declined re-election. The total number of board members will remain six. The meeting resolved to re-elect Heiner Olbrich as Chairman of the Board of Directors. Further the meeting resolved that the remuneration to the Board shall be increased, so that the Chairman of the Board receives SEK 410,000 (previously 375,000) and other Directors SEK 175,000 (previously 150,000) each. The Meeting also resolved that remuneration to be paid to the Directors for work on board committees shall be unchanged, which means SEK 16,000 to each of the members of the remuneration committee and SEK 27,000 to the Chairman of the remuneration committee, and SEK 55 000 to each of the members of the audit committee and SEK 80,000 to the Chairman of the audit committee. Auditors The Annual General Meeting resolved to re-elect Deloitte AB for the period until the end of the next Annual General Meeting. The Meeting also decided that fair remuneration to the auditors shall be paid on approved accounts. Automatic share redemption procedure The Annual General Meeting resolved on an automatic share redemption procedure, including a share split 2:1, in accordance with proposal by the Board of Directors. The procedure means a distribution to the shareholders of SEK 2.00 per existing share. The Annual General Meeting authorized the Board of Directors to set the record date for the share split, which is estimated to occur 29 May 2018. Payment of the redemption amount is estimated to take place by 21 June 2018, through Euroclear. ISIN code for redemption share is SE0011036839 and for original share SE0011036821. Authorization to resolve on new issues of shares, warrants and/or convertibles In accordance with the proposal by the Board of Directors, the Annual General Meeting authorized the Board of Directors, until the next Annual General Meeting, to resolve on new issues of shares, warrants and/or convertibles on one or several occasions, with or without deviation from the shareholders' preferential rights. The reasons for deviating from the shareholders' preferential rights shall be to enable directed share issues for the purpose of acquisitions of companies or businesses, in whole or in part, alternatively for raising capital to be used for such acquisitions. Guidelines for remuneration to the executive management The Meeting adopted the Board of Directors' proposal regarding guidelines for remuneration to the executive management, comprising the managing director and the other individuals in the executive management. Nomination committee The Annual General Meeting approved the nomination committee’s proposal regarding the nomination committee. Other The CEO gave a presentation and answered questions. For further information, please contact: Fredrik Lövstedt, Director of the Board Telephone: +46 708 59 54 80 E-mail fredrik.lovstedt@bjornborg.com  Documents from the AGM are available for download here: https://corporate.bjornborg.com/en/annual-general-meeting-2018/

Team OwnLabs wins Ericsson Innovation Awards 2018

Ericsson (NASDAQ: ERIC) has announced that Team OwnLabs, from Senegal, is the overall winner of the Ericsson Innovation Awards (EIA) 2018 competition. The four finalist teams competed in the EIA 2018 grand final held at the Nobel Museum in Stockholm, Sweden, on May 17, 2018. Aligning with this year’s Nobel Week Dialogue, the theme for the competition – The Future of Truth – challenged student teams to answer the question of how technology can improve the way we find, validate, and share truth in a fully connected world. Exploring this theme, 1,444 university teams representing 107 countries entered the competition to present their innovative solutions. Team OwnLabs, from the Ecole Supérieure Polytechnique de Dakar and Université de Ziguinchor in Senegal, seeks to address the lack of school labs in Africa by offering physics, chemistry and biology classes in a virtual reality environment via a smartphone. Erik Ekudden, Senior Vice President & Chief Technology Officer, Ericsson, says: “The mobile network platform is the most important innovation platform globally. It enables local ideas and initiatives to quickly scale to a global market. We drive technology leadership in the industry with strong ecosystem partners with university collaborations, startups, and established companies. Being at the forefront in commercializing great technologies and business ideas is key to us. The Ericsson Innovation Awards is one way for us to spur innovation and thought leadership with a world-wide challenge which brings new perspectives and unorthodox thinking into the creative processes.” The simplicity of OwnLabs’ idea to help young people find truth through experimental science and reach their full potential was the motivation behind the jury’s decision.  “The team was able to make virtual reality come to life through a very good use-case scenario,” says Curtis Ludwig, Head of Employer Branding at Ericsson. “The judges were completely inspired by their idea and we hope they are able to make a lasting impact in Senegal.” The jury for the 2018 Ericsson Innovation Awards included Mattias Fyrenius, CEO Nobel Media, Patrick Mesterton, CEO and Co-Founder of Epicenter Stockholm, Marina Petrova, Professor at KTH Royal Institute of Technology, and Anita Frisell, Head of Technology Development & Execution at Ericsson Research. The runner up results are: Second place - Team Alfred, Stanford University, Columbia University, and Rochester Institute of Technology, United States. Alfred is an AI-powered personal assistant that gathers information, identifies bias, and sifts through the noise. Third place - Team TL;DR, Indian Institute of Technology, Delhi, Guru Gobind Singh Indraprastha University, Delhi Technological University, India. TL;DR’s platform summarizes and simplifies user agreements to help consumers make informed decisions. Fourth place - Team Open Sesame, Tongji University, China. Open Sesame is a platform that reviews and verifies retail reviews and ratings to ensure a more reliable shopping experience. About the competition The Ericsson Innovation Awards is a global, annual competition that gives students around the world the opportunity to develop new, innovative ideas in collaboration with Ericsson experts. For more information on the finalists, their solutions, and the 2018 competition, visit the Ericsson Innovation Awards 2018 site .  NOTES TO EDITORS For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson Subscribe to Ericsson press releases here . MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) ABOUT ERICSSON Ericsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com

IK Investment Partners acquires Domia Group from Metric Capital

Acadomia is the leading player in the primary, secondary, higher-education and test-prep tutoring markets (at-home, centres and online). Since 1989, Acadomia and its employees have continuously innovated to offer quality learning experiences to more than 1 million families across different geographies, backgrounds, subjects and learning needs. Acadomia now operates a network of 100 agencies and 20,000 tutors dedicated to help over 90,000 students per year meet their academic goals and enhance their educational life. Acadomia is recognised for its unrivalled brand awareness, its customer-satisfaction ratings and the proven academic success of its students. Shiva is one of the leading and the fastest-growing actors in the home cleaning market. Through its network of 165 franchised agencies, Shiva helps its 45,000-strong client-base to improve their quality of life by taking care of their house cleaning on a regular basis thanks to a unique network of 8,000 selected, trained and highly-experienced maids. Shiva is contributing to transform the highly fragmented home cleaning market by delivering a high-quality hassle-free interior experience. Maxime Aiach, President, said: “Philippe, José and I are excited to embark upon the next stage of our growth story with IK by our side. Their expertise and proven track record in growing businesses combined with the dedication of our talented team of professionals will allow us to strengthen our leading market position.” José Dinis added: “Thanks to the support of Metric and Domia Group’s teams and franchisees, the company has been able to achieve remarkable growth over the last five years while delivering enriching new services and experiences to Acadomia’s students and tutors and Shiva’s clients and maids. The Fund’s investment into Domia paves the way for new ambitions.” Philippe Coléon concluded: “Acadomia’s challenge for the next few years is to go on promoting and democratising ever-more personalised and tailored learning while still being recognised by our clients and tutors as the most innovative, academic-success-oriented and agile company in the industry.” Pierre Gallix, Partner at IK, said: “We were impressed with the track record Domia has achieved since its inception. Acadomia has established an enviable and unique position within the French tutoring market by delivering students the best and most innovative solutions and programs. As far as Shiva is concerned, IK will continue to expand its footprint across France. We look forward to working closely with the Founders to support the continued growth of these two exciting brands.” John Sinik, Managing Partner at Metric, commented: “This exit follows our investment in May 2013 and reflects our direct involvement in supporting our portfolio companies to strengthen their operations. We have greatly enjoyed working with the Founders and their teams to grow the business and are extremely pleased with our investment in Domia.” David Scheurl, Partner at Metric, added: “At the time of our investment, we were attracted to the strength of Domia’s brands and business model. During the life of our investment, Domia Group has consistently achieved impressive growth rates, creating a successful exit path for Metric. We wish the company, its teams and IK all the best in their next chapter of growth.” Unitranche facility for the transaction was provided by Tikehau Investment Management. Parties involved: Management: Maxime Aiach, Philippe Coléon, José DinisManagement M&A advisor: Family Finance First (Stéphane Radiguet)Management Legal advisor: Paul Hastings (Aline Poncelet, Jens Waldner)Structuring: CMS – Francis Lefebvre (Pierre Dedieu, Renaud Grob, Laurent Cantoni, Cyrille Kurzaj) IK Investment Partners: Pierre Gallix, Arnaud Bosc, Morgane Bouhenic, Caroline Le HenBuyer M&A advisor: Vulcain (Michael Schor)Buyer Financial Due Diligence advisor: PwC Transaction Services (Martin Naquet Radiguet, Sophie Gerbaud)Buyer Legal advisor: Willkie Farr & Gallagher (Eduardo Fernandez, David Lambert, Philippe Grude, Paul Lombard, Ralph Unger) Metric Capital Partners: John Sinik, David Scheurl, Alastair Balfour, Bjorn Tessiore, Louis RobertSeller Financial Due Dilligence advisor: PwC Transaction Services (David Willems, Pierre-Mikhael Voyer)Seller Strategic Due Dilligence advisor: Advention Business Partners (Alban Neveux)Seller Legal Due Dilligence advisor: PwC Avocats (Jean-Philippe Brillet, Jérémie Schwarzenberg, Yannick Olivier, Bernard Borrely)Seller Legal advisor: DLA Piper (Xavier Norlain, Edouard Sarrazin, Aymeric Robine) Lender Legal advisor: Paul Hastings (Olivier Vermeulen, Aladin Zeghbib)

Interim report January - March 2018

First quarter 2018 ·Revenues amounted to SEK 267.0 (121.3) million, an increase by 120 % compared to the same period last year. ·Operating profit amounted to SEK 140.5 (38.0) million, an increase by 270 %. ·Profit before tax amounted to SEK 140.5 (38.0) million, and profit after tax amounted to SEK 108.8 (29.2) million. ·Cash flow from operating activities amounted to SEK 144.2 (85.7) million, and cash flow from investing activities amounted to SEK -90.3 (-44.6) million. ·By the end of the period cash and short term placements amounted to SEK 373.6 (288.0) million. ·Earnings per share amounted to SEK 1.03 (0.28) per share. ·Revenue from the first quarter of 2018 are mainly attributable to Stellaris, Cities: Skylines, Surviving Mars, Hearts of Iron IV and Europa Universalis IV. Important events in the first quarter ·One new game was released during the period, Surviving Mars, developed by Bulgarian development studio Haemimont Games. ·Several expansions were released during the period; Back to Hell for Steel Division: Normandy 44, Apocalypse for Stellaris, Waking the Tiger for Hearts of Iron IV, Rule Britannia for Europa Universalis IV and Content Creator Pack for Cities: Skylines for console. ·Steam Winter Sale started December 21 and continued until January 4. ·January 2 Paradox acquired 33 % of the shares in development studio Hardsuit Labs, based in Seattle, for USD 2.0 million. Paradox has an option to increase its ownership in the future. Words from CEO A good start to 2018 When we decided to list Paradox Interactive, we chose to do so right after a somewhat mediocre quarter – something that was intentional from our side. In fact, it gave us the chance to properly inform people that our industry is not driven by quarterly results. It’s important for an investor to understand this and view the company and its business long-term. Paradox is not a company for the nervous investor. When we look at first-quarter earnings for 2018, this point is well worth remembering. We have had a good quarter in every way, with a well-defined release schedule. Compared with the previous year’s first quarter, I would even describe the quarter as excellent. It feels extra special because many people in the organization have worked persistently to put together good releases. We have also seen a major boost in the impact of our marketing efforts. Internally we usually say that we focus on the marathon, not the sprint. It’s about having the stamina to reach all the way to the finish line. In the same way that we run the company and our strategies for the long term, we also consider the interaction with our players as long term. Conversions in the form of a game purchase is not the end destination – it’s rather the beginning of our shared journey ahead. This means that every new game release can be viewed as a foundation on which we continue to build together with our community. For example, we can see for several of our games that profitability and the number of players rise steadily over time (in some cases, over the course of several years). This means that the launch period remains important for Paradox, but nowhere near as critical as it was merely a few years ago. Of course, we still aim to attract an active player base that will return to the games on a regular basis. During the quarter, we released a new game and several expansions. We are very pleased with the release of Surviving Mars, which has met the goals and expectations we set in our forecast. In addition, we are very proud to have released the game for the first time on PC, Mac, Linux, PS4 and XboxOne simultaneously across multiple time zones. Overall the game has been well received, especially by critics, although some challenges have dragged down user ratings below the level we are used to seeing for releases. The development team and publishing team are now working on further development of the game, along with the players, to enhance the gaming experience based on player feedback. We also released a number of highly anticipated expansions during the quarter. These stimulate renewed interest in the game, while attracting players back. Hearts of Iron IV: Waking the Tiger sold very well, for instance, even though many loyal players already have the expansion pass for the game. With the release of Europa Universalis IV: Rule Britannia, we broke a new record for number of active monthly players. Stellaris: Apocalypse reached plenty of new players, too, which was evident in two ways: sales were positive and the story trailer was viewed more than 2 million times. Furthermore, Steel Division: Back to Hell was well received in the community thanks to a desire for solo content. In addition, a content creator pack provided Cities: Skylines Console with new content. The content was created by the game’s modders who, through a partnership with Paradox, become co-creators of the game. After the period, Battletech was launched and progressed according to plan with good concurrent user figures, i.e. the number of players playing simultaneously. In January, the entire company gathered at Kolmården for a few days of conferences and team building. There, we talked about the organization and our strategy for the future and we celebrated the 20-year anniversary of Paradox Development Studio in 2018. In March, the Game Developers Conference also kicked off in San Francisco. This year, our primary focus was on our partnerships since we’ll be saving our announcements for PDXCON in May. We also had speakers at the developers conference and contributed speakers to Tencent’s internal conference. This will be the last CEO statement from me alone. As outgoing CEO, I will write the next statement together with Ebba, the CEO-elect. Moving ahead, I look forward to stepping into my new role as executive chairman and letting you get acquainted with our new CEO. I will, however, remain in my position until the end of July, and there is much we want to accomplish both before and after that date! Fredrik Wester, CEO Presentation of interim report Fredrik Wester and Alexander Bricca will host a live stream to answer report and financial related questions on our Twitch channel on May 18 at 12:00 PM CEST https://www.twitch.tv/paradoxinteractive. Submit your questions before via our forum https://forum.paradoxplaza.com/forum/index.php?threads/q1-report-q-a-stream-may-18-12pm-cest-noon.1096412/, by e-mailing them to ir@paradoxplaza.com or directly in the Twitch chat. The Twitch chat is open for anyone to view but to post comments or question you will need to create an account.

AZN: Q1 2018 Results

AstraZeneca PLC                                                                                             18 May 2018 07:00 Q1 2018 Results Encouraging launches and the performance of newer medicines underpin reiterated guidance As expected, the Product Sales performance benefitted from strong launches and the continued growth of newer medicines and China, offset by the erosion of Crestor sales. Progress was made on overall cost discipline, while the level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results. Patients continued to benefit from the progress of the pipeline and AstraZeneca's plans remain on track, with the Company continuing to anticipate Product Sales growth this year, weighted to the second half. Financial Highlights Q1 2018$m % change Actual CER1Total Revenue 5,178 (4) (9)Product Sales 4,985 3 (2)Externalisation Revenue 193 (66) (67) Reported Operating Profit2 696 (24) (21)Core Operating Profit3 896 (46) (47) Reported Earnings Per Share (EPS) $0.27 (37) (29)Core EPS $0.48 (51) (51) · Product Sales increased by 3% (down by 2% at CER). Strong performance of China and newer medicines across all therapy areas was offset by the decline of Crestor sales in Europe and Japan. Total Revenue declined by 4% (9% at CER) to $5,178m, reflecting the level of Externalisation Revenue in the quarter · The Reported Gross Margin declined by five percentage points (four at CER) to 77.3%, a result of the favourable impact of manufacturing variances realised in Q1 2017, as well as the agreement on Lynparza with MSD4; the Core Gross Margin fell by five percentage points (four at CER) to 78.8% · Good progress on overall cost discipline - Reported Operating Expenses were stable (down by 5% at CER) at $3,817m; Core Operating Expenses increased by 3% (but declined by 1% at CER) to $3,349m. Reported R&D costs declined by 12% (16% at CER) to $1,279m; Core R&D costs declined by 7% (12% at CER) to $1,240m, driven by efficiency savings. Reported SG&A costs increased by 7% (2% at CER) to $2,457m; Core SG&A costs increased by 11% (6% at CER) to $2,028m, reflecting investment in China and new medicine launches · Reported Other Operating Income & Expense increased by 99% (97% at CER) to $469m, a result of a legal settlement; Core Other Operating Income & Expense declined by 63% (64% at CER) to $124m, impacted by the timing of divestments · Reported EPS of $0.27 and Core EPS of $0.48 · Capital expenditure reduced to $213m (Q1 2017: $286m). Restructuring costs reduced to $95m (Q1 2017: $312m), supporting an anticipated decline over the full year · FY 2018 guidance reiterated and unchanged  Please refer the attached PDF to view the full announcement. This information is provided by RNS The company news service from the London Stock Exchange

Six patients now treated with NextCells ProTrans stem cells

The trial performed with NXTCL's drug candidate ProTrans, is divided into two parts, the first part being a dose-escalation phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now all patients in the low-dose-cohort and the medium-dose-cohort have been treated. After the 1-month follow-up of the medium-dose-cohort is completed we can start inclusion of patients in the high-dose-cohort. Both the treatment and follow-up procedure are the same for the high-dose-cohort. The second part of the trial is a randomized, double-blind, placebo-controlled trial in which 10 patients receive ProTrans and 5 patients receive placebo. In this trial a total of 24 patients will be treated with ProTrans. The primary safety endpoint is drug safety and the primary efficacy endpoint is the change in insulin production after 1 year. The clinical trial is conducted by the Karolinska Trial Alliance and headed by Professor Per-Ola Carlsson from Uppsala University, who is the principal investigator for the trial. The Data Safety Monitoring Board for the trial consists of Professors Ulf Smith and Anders Fasth from the University of Gothenburg, and Åke Lernmark from Lund University. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on April18th, 2018.

2018 Q1 report, Period January-March for Panion Animal Health AB

Period January-March · Net sales: kSEK 0 (0).  · Operating profit: kSEK -697 (-1 267). · Earnings per share: SEK -0,05 (-0,11). · Liquidity at the end of the period: kSEK 2 708 (102). Significant events after the end of the period: · On April 25, 2018, the annual report was published. · On May 4, 2018, the board of Panion decided to start a new emission of shares. Terms and conditions can be seen on Panion’s website. Milestones January-March 2018  · On January 3, 2018, Panion entered into a financing agreement with the Yorkville Advisory Global Yorkville (Yorkville). As investment manager, and on behalf of one or more of its investment funds, Yorkville decided to purchase convertible debentures up to SEK 9,000,000 by Panion Animal Health AB. · On January 3, Panion entered into a financing agreement with Dividend Sweden, which has decided to purchase convertible debentures of SEK 500,000 by Panion Animal Health AB. · On January 3, it was also announced that the FDA has established an investigative veterinary drug application (INAD) for Panion’s development product for gene therapy for dog epilepsy. · On January 19, Panion’s head of regulatory affairs, Niels-Erik Manniche, decided to leave the company. He was available to the company until March 31st. His duties are covered internally until further notice. · On February 16, 2018, we announced that an international study that is independent of Panion’s and CombiGenes’s research, but which uses the same neuropeptide NPY for the treatment of rats with chronic and generalized epilepsy, was published online. The study shows both reduced number and duration of seizure in rats and increases the knowledge of NPY’s effect in different brain regions. · On February 19, 2018, final data from CombiGene’s long-term rat study show clearly positive effects in terms of fewer and shorter attacks. This is directly relevant to the development of Panion’s gene therapy product for dogs. · On March 6, CEO Anja Holm presented Panion’s plans, progress, and future for Feminvest investors at an event in Malmö. A video link in English is available on our website. · On March 13, we announced the cooperation with biostatistician Steve Radecki (USA) with regards to the coming clinical study in dogs with epilepsy. · On March 14, 2018, the first conversion of Yorkville’s convertible debentures to shares took place. Panion Animal Health AB’s Board of Directors has, under the terms of the Panion financing arrangement and an investment fund managed by Yorkville Advisors Global announced on January 9, 2018, decided to approve Yorkville’s request to convert a share of SEK 200,000 of the convertible debt securities to shares. · In Q1, the planned safety study in dogs was started in cooperation with Copenhagen University and under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. The announcement of the start of the study was released on April 25. · The preparations for a pilot field trial in the USA continued with the assistance of the US consultants and investigator. CEO statement CEO statement Panion’s business and product development would not be possible without the support of all our investors and cooperation partners, so first I wish to send out a grateful thanks to you! The first quarter of 2018 in Panion has been dedicated to two intensive and important issues; the start of a dog study, and the financial structure for future business and trials. The dog study was planned and is running under the lead of Associate Professor David Woldbye from the University of Copenhagen, Department of Neuroscience. It will lead us to a better understanding of the safety of the vector, secure the data we need in terms of vector behavior, and hopefully help to expand the potential patient base for the product in the longer run. The results are expected to be released in Q3 of this year. For a small company, it is essential that there is a robust financial underpinning of the future plans before contracts can be signed with researchers and other businesses. Panion’s chairman of the board has secured a future-based solution, so the next steps in our product development can be started. Running a clinical trial, even a smaller version of a clinical trial engaging client-owned animals in the study, is a major undertaking and we want to ensure that we succeed in the best possible way. Panion’s epilepsy product is a very innovative treatment, and close cooperation with the regulatory authorities is necessary. We are therefore very pleased that the European Medicines Agency has invited us to a meeting with their Innovation Task Force. The meeting will create a possibility for their scientific and regulatory experts to learn about our project, and for us to ask their view on some of the steps in the development plan. We hope to benefit a lot from this meeting, and we are sure that it will increase the regulators understanding of the technology and the prospects we see in it. Epilepsy in dogs is a serious disease that affects millions of family dogs across the world and for which medicine is not effective in approximately 30% of cases. The prospect of treating epilepsy – and other chronic diseases in animals – with gene therapy is very promising and we continue to work hard to realize the potential. It is Panion’s ambition to extend our product portfolio and we will continue our search for a promising and accessible product candidate in the coming time. The biotech world is booming again after the difficult years with the financial crisis and we hope to lift the potential of an interesting human project over to the veterinary field and develop it for the benefit of the animals. We will continue to inform about the progress and development as early as possible and within the framework of the stock market. I encourage you to follow our news and read more details about Panion on our website in both Swedish and English. Anja Holm,CEO, Panion Animal Health AB

Beijer Ref acquires French air conditioning distributor GH2C

The Swedish refrigeration wholesale group, Beijer Ref AB, has entered into an agreement to acquire the assets of the French HVAC distribution company GH2C. GH2C is based in Lyon and also has a sales office in Grenoble. The company is a distributor of the renowned air conditioning brands Daikin and Toshiba in France. GH2C delivers AC units within the professional as well as the residential segment. Reported yearly turnover is approximately SEK 60 million. Sales are made through a distribution network with two branches. In total, the company has 11 employees. GH2C adds to Beijer Ref’s existing three refrigeration and HVAC wholesalers in France. Per Bertland, CEO of Beijer Ref, comments: “The acquisition of GH2C further strengthens our position in our largest market France, and in Southern Europe as a whole. Comfort cooling as an area that continues to grow. To be able to complement our offer with full product ranges of leading brands, as well as an expanded distribution presence, generates further market opportunities for Beijer Ref.” GH2C management will continue to take an active part in the company. GH2C will be integrated into Beijer Ref’s organisation and included in the company’s accounts from 1 May 2018. The acquisition is not expected to affect the Group’s earnings or financial position significantly.  Malmö, 18 May 2018 Beijer Ref AB (publ) For further information, please contact: Per Bertland, CEO Telephone +46 40-35 89 00 Email pbd@beijerref.com Maria Rydén, CFO Telephone +46 40-35 89 00 Email mrn@beijerref.com  BEIJER REF AB is a technology-oriented trading Group which, through added-value products, offers its customers competitive solutions within refrigeration and climate control. Beijer Ref is one of the largest refrigeration wholesalers in the world, and is represented in 36 countries in Europe, Africa, Asia and Oceania. www.beijerref.com

Engebø rutile and garnet: New Project Manager

Nordic Mining has appointed Kenneth Nakken as new Project Manager for its rutile and garnet project in Naustdal in western Norway. Nakken has been Vice President, Digital Service in ABB Marine and has broad management and project coordination experience from various management positions in the ABB Group. Nakken will be based in Naustdal and head the project team for the final development work, construction and commissioning of the Engebø operations. CEO Ivar S. Fossum comments: “I am pleased to welcome Kenneth to our team. He has highly relevant experiences for the transitional process to realise the Engebø rutile and garnet project, and its long-term value proposal as a regional cornerstone industry.” For further information please contact CEO Ivar S. Fossum, telephone +47 93096850.Oslo, 18 May 2018Nordic Mining ASANordic Mining ASA (www.nordicmining.com)  Nordic Mining ASA ("Nordic Mining" or "the Company") is a resource company with focus on high-end industrial minerals and metals in Norway and internationally. The Company's project portfolio is of high international standard and holds a significant economic potential. The Company's assets are in the Nordic region.Nordic Mining is undertaking a large-scale project development at Engebø on the west coast of Norway where the Company has rights and permits to a substantial eclogite deposit with rutile and garnet. Permits for the project have been granted by the Norwegian government, and a prefeasibility study was completed in October 2017. Nordic Mining's associated company Keliber in Finland is in the process of completing its definitive feasibility study and preparing for production of lithium carbonate. Nordic Mining has rights for exploration and production of high-purity quartz in Kvinnherad in Norway. Further, the Company holds exploration rights at Reinfjord in northern Norway where a prospective area of sulphide mineralisation has been discovered. Nordic Mining is also exploring opportunities related to seabed mineral resources.Nordic Mining is listed on Oslo Axess with ticker symbol "NOM".

Cereno Scientific has issued the second tranche

The convertible bonds are issued at a price corresponding to 100 percent of the nominal value, which means that Cereno will be provided with SEK 3,500,000. Conversion of the convertible bonds may be requested, in full or in part, by the convertible holder during the twelve months period immediately following registration of the convertible bonds by the Swedish Companies Registration Office. The conversion price amounts to 93 percent of the lowest daily VWAP according to the AktieTorget’s market official price list for the share of class B in the Company during the fifteen (15) trading days preceding the day for the demand for conversion. The convertible bonds are issued with 125,000 warrants attached, that entitle European High Growth Opportunities Securitization Fund to subscribe for additional 125,000 ordinary shares of series B within five years, at a subscription price of SEK 8,4 per share. The warrants are issued free of charge. At full exercise of the warrants, Cereno will be provided with approximately SEK 1,050,000 corresponding to 30 percent of the nominal amount of the convertible bonds. The board’s issue resolutions have been made based on the authorization from the shareholders’ meeting on 19 April 2018. For more information, please contact:Sten R. Sörensen – VDTel: +46 73 374 03 74E-mail sten.sorensen@cerenoscientific.comwww.cerenoscientific.com About Cereno Scientific ABCereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. The benefit with Cereno Scientific’s drug candidate, CS1, is an improved balance between preventing thrombosis and treatment-related side effects – leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on AktieTorget since June 2016 with the ticker CRNO B, ISIN SE0008241558. This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made available publically by the Company’s contact person on 18 may 2018.

Ziccum attracts powerful new Board

Ziccum AB, a subsidiary of ISAB, is commercializing a dry powder air drying system that could revolutionize how vaccines and drugs are formulated and transported. It dries them at room temperature—transforming them into stable dry powders that are cheap and easy to transport, from often delicate, difficult-to-transport liquids. Ziccum attracted capital funding of 2.25 MSEK in 2018 and expects to be listed independently in Q4 2018. “Our three new members bring even more business and pharmaceutical skills to the table,” says Göran Conradson “combining decades-long experience in drug and business development.” The three new Ziccum Board members Ola Camber PhD and Assoc. Prof. in Pharmaceutics and Biopharmaceutics, is an expert in drug formulation/delivery. He is CEO and Founder of ClinStorage AB. With decades of experience in the health care sector e.g. Director of Pharmaceutical R&D at Astra/AstraZeneca, VP Drug Development and Board member at Biotech Companies and Senior Adviser at Karolinska Institutet Innovation AB, Ola is a Member of the Review Panel of the Swedish Research Council.  Mattias Münnich is VP for Business at Stayble Therapeutics and Head of Life Sciences at high-profile innovation and incubation hub Chalmers Ventures. Mattias is a driven veteran of biotech start-up ventures. He guides complex products and drugs to market through Clinical Trials and has contracted GMP manufacturing, designed regulatory strategies, negotiated clinical study agreements, met with some of big pharma’s top business development executives—and more. Kristian Kierkegaard has a background in investment banking as a sell-side equity researcher and sales analyst. He is the CEO and founder of a private asset management company focused on financing small- and mid-cap growth companies. Kristian has a strong track record in equity finance and has a M.Sc. in Finance from Jönköping International Business School and Singapore Management University. Alongside Ziccum, Kristian serves on the Board of private equity company AGOF Investments. Current long-term members are CEO Göran Conradson, CFO Michael Owens (currently CFO of parent company ISAB too) and Board Chairman Fredrik Sjövall, (outgoing CEO of parent company ISAB and its next Board Chairman).

BerGenBio to present interim clinical and biomarker data with selective AXL inhibitor bemcentinib in AML and MDS at EHA

Presentations at EHA Saturday 16 June, 5:30 - 7:00 PM CEST  Ph II trial with selective oral AXL inhibitor bemcentinib (BGB324) in relapsed/refractory AML and MDS: Identification of predictive and pharmacodynamic biomarker candidates associated with pt benefit  · Sonja Loges, MD, PhD et al · Session: Acute myeloid leukemia - Clinical  · Abstract code: PS981 Single cell signaling pharmacodynamics and clonal evolution in a phase I/II clinical trial of selective AXL inhibitor bemcentinib (BGB324) in R/R acute myeloid leukemia and myelodysplastic syndrome · Monica Hellesøy, PhD et al · Session: Acute myeloid leukemia - Biology & Translational Research  · Abstract code: PS965  -End-  About BerGenBio ASA  BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy. The Company is a world leader in understanding the essential role of AXL kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers.BerGenBio’s lead product, bemcentinib (BGB324), is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated during 2018. It is the only selective AXL inhibitor in clinical development.The Company sponsored clinical trials are: · Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC) · Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and · Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC). · Bemcentinib as a single agent and combination therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS)  The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth, NJ, USA), through a subsidiary.  In addition, a number of investigator-sponsored trials are underway, including a trial to investigate bemcentinib with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining bemcentinib with docetaxel in advanced NSCLC.  BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with bemcentinib. This will facilitate more efficient registration trials and support a precision medicine based commercialization strategy.  The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody.For further information, please visit: www.bergenbio.com   KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc.  Contacts  Richard GodfreyCEO, BerGenBio ASA+47 917 86 304  Rune Skeie, CFO, BerGenBio ASArune.skeie@bergenbio.com+47 917 86 513  Media Relations in NorwayJan Petter Stiff, Crux Advisersstiff@crux.no+47 995 13 891  International Media RelationsDavid Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogersonbergenbio@citigatedewerogerson.com+44 207 638 9571  This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Largest co-located battery installed in the United Kingdom

The 22MW facility, which shares electrical infrastructure with the Pen y Cymoedd wind farm, will help UK National Grid maintain frequency levels and reliability of electricity supply, by storing electricity produced by the wind farm, Gunnar Groebler, Senior Vice President Business Area Wind, said: “Vattenfall is on the road to a smart, digitalised future, free from fossil fuels. I can think of few other energy installations that better demonstrate what that future looks like than this battery installation.” The battery is made up of six shipping container sized units, five of which house 500 i3 BMW manufactured battery packs. It uses new lithium-ion batteries with a capacity of 33 kilowatt hours (kWh) supplied by BMW and adapted for a stationary application. Claus Wattendrup, Head of Business Unit Solar & Batteries, said: “This is Vattenfall’s largest battery installation to date, where we make use of synergies at our existing wind farms sites – such as at Pen y Cymoedd or the Princess Alexia Wind Farm in the Netherlands. Hybrid renewable parks will play a larger role in the future and we are leading this development.”The 76-turbine Pen y Cymoedd onshore wind farm is capable of meeting the equivalent electricity needs of more than 13% of households in Wales every year. It also boosts delivery of Wales’s climate change ambitions, displacing in an average year more than 300,000 tonnes of CO2 from fossil fuelled generation. For more information, contact:Vattenfall Press Office +46 8 739 5010, press@vattenfall.com  Vattenfall is a leading European energy company, that for more than 100 years has electrified industries, supplied energy to people’s homes and modernised our way of living through innovation and cooperation. We now want to make fossil-free living possible within one generation. Therefore we are driving the transition to a more sustainable energy system through growth in renewable production and climate smart energy solutions for our customers. We employ approximately 20,000 people and have operations mainly in Sweden, Germany, the Netherlands, Denmark, the UK and Finland. Vattenfall is owned by the Swedish state. For more information: corporate.vattenfall.com  

Sustainable Transport Forum 2018 gathers world leaders to discuss the shift to a fossil-free transport system

Professor Johan Rockström, one of the world's leading researchers on sustainability issues, will lead the forum. He will, together with speakers and panellists representing governments, cities, international organisations, industry, academia and civil society, stimulate discussions on defining a clear direction for sustainable transport. The transport sector accounts for a significant share of global greenhouse gas emissions. With urbanisation and social and economic development, the need to transport people and goods increases. It is obvious that progress in the transport industry will contribute to reaching many of the sustainable development goals. “At Scania we have made our choice. We have taken the decision to be an active leader in the shift towards sustainability in our sector. However, it is only through continued collaboration that we can achieve real change. This is why we gather leaders and decision makers at the Sustainable Transport Forum; to come together to discuss how we can unite, simplify and, most importantly, speed up the pace of change,” says Henrik Henriksson, Scania’s President and CEO. The forum will discuss what is required to globally reach fossil-free commercial transport by 2050 at the latest, which is the speed of change required. The opportunities for change that are available already here and now will also be a topic of discussion. “We are committed and we are convinced that we can achieve a fossil-free transport system globally by 2050 in order to meet the Paris agreement target. To make the shift happen, we need to keep challenging ourselves, our partners, our customers, their customers, policy-makers and academia. Scania wishes to be part of the solution and can substantially contribute to reaching the target,” Henriksson says. In 2016, Scania hosted the first Sustainable Transport Forum  to underline its commitment to lead the shift towards a fossil-free transport system. For further information, please contact: Karin Hallstan, Public Relations Manager, phone: +46 76 842 81 04, e-mail: karin.hallstan@scania.com

AMPK activator O304 A novel potential treatment for diabetic kidney disease

Diabetic kidney diseaseGlobally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard of care consists of antihypertensive medication (ACEi/ARB inhibitors), and regulation of the blood sugar level as part of regular diabetes care, but with very limited efficacy. Thus, in addition to risks, personal suffering, and reduced quality of life for millions of people, DKD is associated with billions in costs to society. No new drugs - SGLT2 inhibitors?Despite decades of research on various mechanisms including fibrosis and inflammation there have not been any new drugs approved in the last 15 years for the treatment of chronic kidney disease. Glomerular hyperfiltration is common in type 2 diabetic patients and believed to cause a later decline in filtration rate (eGFR) and in kidney function. Reduced renal filtration/hyperfiltration is currently the only mechanism that shows efficacy in DKD. ACEi/ARB inhibitors act directly on the vascular system to reduce hyperfiltration. SGLT2 inhibitors are recently introduced anti-hyperglycaemic agents that show improved renal outcome in T2D patients with established cardiovascular disease. SGLT2 inhibitors act indirectly via the tubular system on the renal vascular system to cause an initial decline in eGFR that then stabilizes. In contrast, eGFR steadily declines in patients who develop DKD. SGLT2 inhibitors are currently, however, contra-indicated in T2D patients with impaired renal function. AMPK activator O304 as a novel potential treatment for DKDMultiple interventional studies in animal models have suggested potential beneficial effects of AMPK activation in DKD. Post hoc analyses of phase I and phase IIA clinical trials of O304, an AMPK activator in development, show that O304 lowers blood pressure and potently reduces eGFR by a rapid, stable and reversible hemodynamic effect both in obese non-diabetic subjects and in T2D patients, and that O304 is at least as potent as SGLT2 inhibitors. Moreover, O304 also reduces eGFR in T2D patients treated with ACEi/ARB inhibitors i.e. standard of care, indicating different mechanisms of action of O304 compared to both ACEi/ARB and SGLT2 inhibitors. Hyperglycemia, hyperinsulinemia and insulin resistance are also implicated in the development of DKD, and all are reduced by O304 both in diet induced obese mice and in T2D patients. Thus, AMPK activator O304 may exhibit both hemodynamic and metabolic effects that are beneficial for preventing the development of DKD in T2D patients. O304 may also prevent chronic kidney disease in obese non-diabetic individuals. O304 and SGLT2 inhibitors in combinationSGLT2 inhibitors are currently contra-indicated in T2D patients with impaired renal function due to lack of anti-glycemic efficacy in this group of patients. However, O304 and SGLT2 inhibitors in combination potently and synergistically reduce hyperglycemia, hyperinsulinemia and insulin resistance in diet induced obese mice. Due to the apparent divergent vascular and tubular mechanisms of action of these two classes of compounds one may also expect a beneficial combinatorial renal hemodynamic effect. Thus, O304 in combination with a SGLT2 inhibitor may both improve glucose homeostasis and prevent DKD in T2D patients. In particular, in the recently identified subgroup 3 of T2D patients that are obese (BMI ~35), insulin resistant, hyperinsulinemic and have a 5 fold higher risk of developing DKD, and that currently lack efficient treatment [1]. Betagenon AB is a privately owned Swedish Biotechnology company.Betagenon AB has received funding from EU's research and innovation framework programHorizon 2020 (EU project 754268 - AMPK-DIAB). Contact: thomas.edlund@betagenon.com [1] Ahlqvist et. al., Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6:361-369, 2018. 

Frans Ryden appointed CFO

Frans Ryden has 20 years of experience in finance, including more than 14 years with Mondelez in various finance positions. With Mondelez Frans held positions such as chief financial officer for India and for Indonesia, finance director Asia-Pacific, regional manager financial planning and analysis, and area manager internal controls. He currently holds a position as Vice President finance for Arla Foods at the company’s head office in Denmark. He was born in 1972 and holds a BSc in Business Administration from the Stockholm University and a Master of Laws from the Stockholm University. “I am very happy to welcome Frans Ryden to Cloetta’s Group Management. He has a solid and proven track record from various finance positions in the fast moving consumer goods industry”, says Henri de Sauvage-Nolting, President and CEO of Cloetta. An interim finance organization (including M&A and IT) has been set up as from 16 July when the current CFO, Danko Maras, is leaving Cloetta, up until Frans Ryden takes up the position. Johnny Engman, Senior Vice President Corporate Development and M&A and member of Cloetta’s Group Management, has decided to leave Cloetta to take up a role as CFO/COO in another company. “Johnny Engman has played an instrumental role in all the mergers and acquisitions Cloetta have done. I would like to express our sincere thanks and appreciation for his excellent work during his six years with the company. It is my intention to continue to build on the M&A work that Johnny Engman has developed, says Henri de Sauvage-Nolting.

Minesto News Update 18 May 2018

MGS buoy on the move Minesto has completed preparations for installation of the micro grid system (MGS) buoy that will be used with the first Deep Green device in Holyhead Deep, Wales. The buoy was lifted from the King George V dock to the River Clyde in Glasgow and will now be towed to Holyhead for upcoming installation at Minesto’s site off the North West Welsh’ coast. Read more here . Minesto pitch at reputable EU event Yesterday, Minesto attended the Blue Invest matchmaking event in Brussels organised by the European Commission. Minesto was one of 20 companies from four different blue economy sectors, selected from a list of 120 applicants, that got the opportunity to pitch their investment case in front of a jury of professional investors. In addition, Minesto’s CEO Martin Edlund was given the chance to meet and network with other potential business partner and high-level stakeholders. The event was attended by influential stakeholders such as Karmenu Vella, EU Commissioner for Environment, Maritime Affairs and Fisheries and European Investment Bank Vice President Jonathan Taylor. In his opening speech, Commissioner Vella said: “Our experience shows that investors trust big brands and tried-and-tested technologies. Meanwhile, start-ups and scale-ups, especially in emerging areas like ocean energy or blue biotech, are struggling to raise much smaller sums. It’s an issue of visibility. And it’s an issue of credibility as well. And in both cases the European Commission is ready to help.” Read more at MarineEnergy.biz . Meet Minesto at Swedish shareholder event next week On Tuesday 22nd of May, Minesto will participate at Swedish shareholder event Aktiedagen Malmö, organised by Aktiespararna and held at Kockum Fritid. CEO Martin Edlund will present Minesto at 13:20 and we will also be in the company lounge before and after the presentation. For those who are unable to be there in person, the day is broadcasted live via this link . For more information and registration, see this link .

Triumph Studios and Paradox Interactive Announce Age of Wonders: Planetfall

STOCKHOLM - MAY 19, 2018 - Paradox Interactive today announced Age of Wonders: Planetfall, a new upcoming strategy game from Triumph Studios, creators of the critically acclaimed Age of Wonders and Overlord series. Slated for release for PC and console in 2019, Planetfall will bring all the exciting turn-based empire building and immersive tactical combat of its predecessors to an all-new sci-fi setting. https://www.youtube.com/watch?v=WTHxBqqNONA In Age of Wonders: Planetfall, players will emerge from the dark age of a fallen galactic empire to craft a new future for their people. Exploring the planetary ruins and encountering other surviving factions that have each evolved in their own way, players will unravel the history of a shattered civilization. Fight, build, negotiate and technologically advance the way to utopia, in a deep single player campaign, on random maps and against friends in multiplayer.    “We’re thrilled to finally announce our latest endeavor alongside Paradox,” said Lennart Sas, Triumph Studios CEO. “Age of Wonders: Planetfall is roughly three years into development, running on a new generation of our multi-platform Creator Engine. While the setting is new, we’re confident that Age of Wonders fans will feel right at home exploring the remnants of the Star Union. Our aim is to make a game that greatly expands upon its predecessors, and still employs the core principles that made Age of Wonders such a success.”  Key Features: ·Strategic Turn-Based Sci-Fi Combat -  Perfect your combat strategy in intense turn-based battles that offer tactical challenges, a large cast of races, units with customizable weapons, and destructible environments. ·Discover a Rich Science Fiction World - Uncover the history of the fallen galactic empire as you explore lush landscapes, and experience the emergent story. Encounter NPC factions and rival houses, and discover hidden technologies that can strengthen your society and give you advantage over enemies. ·Planetary Empire Building  - Create your own unique House, and build prosperous colonies through economic specializations of planetary sectors and governing doctrines. ·Multiple Paths to Victory - Achieve your end goals through conquest, diplomacy or doomsday technologies. Engrossing options with NPC factions and rival Houses won’t make the decisions easy! Those eager to get more information about Age of Wonders: Planetfall can sign up for the newsletter, and help unlock special community rewards at www.aow-planetfall.com.

Paradox Interactive Brings Grand Strategy to the Tabletop with New Board Games

STOCKHOLM - May 19, 2018 - Paradox Interactive, a global developer and publisher of games that get a little dicey, today announced that it is working with industry-leading publishers to bring its best-selling and award-winning games to the tabletop with a series of Paradox board games. This morning at PDXCON, the publisher’s annual fan convention, it was announced that Paradox is collaborating with a series of proven board game designers to bring its own game worlds to life outside of digital platforms. Beginning with Paradox’s iconic series Crusader Kings, Europa Universalis, Hearts of Iron, and Cities: Skylines, the creators at Paradox will capture the strategy and themes of its games in tabletop form, allowing players to tell their own stories in a new way. Get a first glimpse of Paradox’s upcoming tabletop titles in a new board-approved trailer: https://youtu.be/Db7AMzYaYyU The first game to be produced will be the Crusader Kings board game, designed and published in cooperation with Free League Publishing, developers of the award-winning tabletop roleplaying games Mutant Year Zero and Tales from the Loop RPG. Players will compete in Crusader Kings for military, religious, and political power while keeping their personal dynasty strong, using cards and miniatures to experience the iconic medieval intrigue of Paradox’s long-running PC franchise. The Crusader Kings board game is available to back on Kickstarter as of this morning, and can be found here: https://www.kickstarter.com/projects/1192053011/1481810177

Hearts of Iron IV Celebrates One Million Sales With Anniversary Edition

STOCKHOLM - 19 May 2018 - Paradox Development Studio is very happy to announce that its grand strategy wargame Hearts of Iron IV has sold one million copies. This is the third of its historical titles, after Crusader Kings II and Europa Universalis IV, to hit the one million market, and is evidence of a strong and durable market for challenging games about our shared past. Hearts of Iron IV offers players unparalleled flexibility in exploring new historical paths and pursuing hundreds of “what if?” alternate futures, tied to a powerfully flexible war planning system that gives people control over wide fronts, amphibious operations and the air and sea. Hearts of Iron IV celebrates the one million milestone and its second anniversary by announcing a special physical bundle for collectors and newcomers alike, that includes a special historical diorama designed by Power Up Factory. "When we released Hearts of Iron IV we didn't know it was going to be such a success,” says Dan Lind, Game Director for Hearts of Iron IV..  “We did not dare make a big physical collector’s edition. It feels great to be able to make something like that now. Both as Game Director and as someone who loves miniatures!". Mike Horn, CEO and President of Power Up Factory, is also very excited about the alternate history model his team got to design - the Italian Army raising its flag on the ruins of London. “We’ve made a lot of interesting collectibles here, but this one’s a first for sure,” says Horn. “I lived in the Washington, DC area for many years and saw the real life Iwo Jima statue countless times. To now be able to make a creative interpretation of it? Amazing!” Lind adds, "You know you have the right job when you can dream up alt-history scenarios for your game and someone makes a big ass amazing statue of it!" The Hearts of Iron IV Anniversary Edition will include: ·Historical Diorama from Power Up Factory: A hand-painted collector’s diorama from the experts of game memorabilia. This diorama depicts an alternate history, with the Italian army raising its flag over the ruins of London. ·Hearts of Iron IV: Man the Guns: The newest expansion to Hearts of Iron brings greater depth and customization to the naval aspect of war, new National Focus options for the United States, unique actions for democracies and much more. ·Hearts of Iron IV Base Game: A Steam key of the best-selling grand strategy wargame that tests your understanding of subtlety, supply and strategy to keep or share with a friend. If you want to spend a little extra, your Anniversary Edition can also include keys for every other Hearts of Iron IV expansion: Together for Victory, Death or Dishonor and Waking the Tiger. For complete information on the Hearts of Iron IV Anniversary Edition, check out the product page at hoi4.paradoxplaza.com.

Sobi emphasises commitment to haemophilia community at WFH 2018 World Congress

Recent data show quality-of-life improvements for patients treated prophylactically with Elocta® and Alprolix®, extended half-life haemophilia therapies. Swedish Orphan Biovitrum AB (publ)  (Sobi™)(STO:SOBI) will present data at the World Federation of Hemophilia (WFH) 2018 World Congress, in Glasgow, Scotland, 20-24 May, demonstrating the company’s ongoing commitment to transforming the standard of care for people with haemophilia. Sobi will present real-world data demonstrating improvements in quality-of-life measures, including physical activity and joint pain, in patients treated prophylactically with Elocta (efmoroctocog alfa) for haemophilia A and Alprolix (eftrenonacog alfa) for haemophilia B, when compared with standard half-life factor treatments. Elocta and Alprolix are extended half-life haemophilia therapies with well-established safety and efficacy profiles and close to four years of real-world experience, supported by a growing body of real-world evidence from thousands of patients across all age groups. “We continue to advance our scientific understanding of our therapies’ impact on disease burden,” said Armin Reininger, Senior Vice President, Head of Medical and Scientific Affairs at Sobi. “By gathering data on outcomes such as physical activity and joint health status, we maintain our focus on research that reflects a meaningful difference for patients, providing protection beyond bleed prevention. The real-world data generated thus far support the safety profile of our products. Since both products are indicated for all age groups, in prophylaxis, on-demand as well as in surgery, they also provide the opportunity for individualised treatment.” Sobi will present a total of four abstracts including a joint presentation with Bioverativ Inc., a Sanofi company: Sobi presentations · Patient Reported Outcomes on Ways to Improve Haemophilia Care: Results from the CHESS Study: Wednesday, 23 May, 15:45-16:30. Poster #78 · The effect of switching to rFVIIIFc on treatment patterns and annualised bleed rate before and after: a within-patient comparison from the UK National Haemophilia Database: Wednesday, 23 May, 16:30-18:00. Oral presentation Do EHL products meet patients’ expectations (the HOPE study): Tuesday, 22 May, 16:30-18:00. Oral presentation Sobi and Bioverativ – joint presentation Economic impact of recombinant factor VIII Fc fusion protein (rFVIIIFc) compared to conventional factor VIII for immune tolerance induction (ITI) of Hemophilia A patients with inhibitors. Monday, 21 May, 16:30-18:00. Poster presentation #77 All oral and poster presentations can be accessed at the WFH 2018 World Congress website here.  In addition, Sobi and Bioverativ will co-host two scientific symposiums at the congress. · Advances in Haemophilia: Factor-Based Therapies and Long-Term Evidence versus New Treatment Modalities.  Monday, 21 May, 18:15 – 19:45, Hall 3, Scottish Event Campus. The session will be chaired by K. John Pasi, Professor, MD, PhD, Barts and the London School of Medicine and Dentistry, London and will be open to healthcare practitioners only. · Inhibitor Eradication: Clinician and Patient Perspectives on Safety Considerations and Long-Term Outcomes.  Tuesday, 22 May, 12:30-14:00, Hall 2, Scottish Event Campus. The session will be chaired by Victor Blanchette, MD, MA, MB, Pediatric Thrombosis and Hemostasis Program, The Hospital for Sick Children, Toronto and is open to all congress attendees. ----About Elocta®Elocta® (efmoroctocog alfa) is a recombinant clotting factor therapy developed for haemophilia A using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Elocta is manufactured using a human cell line in an environment free of animal and human additives. Elocta is approved and marketed by Sobi for the treatment of haemophilia A in the EU, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland. It is approved and marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] by Bioverativ in the United States, Japan and Canada. It is also approved in Australia, New Zealand, Brazil and other countries, where Bioverativ has the marketing rights. As with any factor replacement therapy, allergic-type hypersensitivity reactions and development of inhibitors may occur in the treatment of haemophilia A. Inhibitor development has been observed with Elocta, including in previously untreated patients. For more information, please see the full U.S. prescribing information  for ELOCTATE. Note that the indication for previously untreated patients is not included in the EU Product Information  for Elocta.  About Alprolix®Alprolix® (eftrenonacog alfa), is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). Alprolix is manufactured using a human cell line in an environment free of animal and human additives.Alprolix is approved and marketed by Sobi for the treatment of haemophilia B in the EU, Iceland, Kuwait, Liechtenstein, Norway, Saudi Arabia and Switzerland, as well as in the United States, Canada, Japan, Australia, New Zealand, Brazil and other countries where Bioverativ has the marketing rights. Allergic-type hypersensitivity reactions and development of inhibitors have been observed with Alprolix in the treatment of haemophilia B, including in previously-untreated patients. For more information, please see the full U.S. prescribing information  for Alprolix. Note that the indication for previously-untreated patients is not included in the EU Product Information.  About haemophilia A and BHaemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually, and more rarely in females. Haemophilia B occurs in about one in 25,000 male births annually, and more rarely in females. The World Federation of Haemophilia estimates that approximately 180,000 people are currently diagnosed with haemophilia A and B worldwide.[i]  People with haemophilia A or B experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Prophylactic infusions of factor VIII or IX can temporarily replace the clotting factors that are needed to control bleeding and prevent new bleeding episodes.[ii]  The World Federation of Hemophilia recommends prophylaxis as the optimal therapy as it can prevent bleedings and joint destruction.[iii]  About the Sobi and Bioverativ collaborationSobi and Bioverativ, a Sanofi company, collaborate on the development and commercialisation of Alprolix and Elocta/ELOCTATE. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Bioverativ has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory, and has manufacturing responsibility for Elocta/ELOCTATE and Alprolix. While Fc fusion technology has been used for more than 15 years, Sobi and Bioverativ have optimised the technology and are the first companies to utilise it in the treatment of haemophilia. In 2014, Sobi added the rFVIIIFc-XTEN-vWF fusion molecule for potential treatment of haemophilia A, to the collaboration agreement.  About Sobi™Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that make a significant difference for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.  For more information please contact Media relations Sobi Investor relations SobiLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager President, Head of Investor Relations+46 70 873 40 95 +1 347 224 0819, +1 212 579 0506linda.holmstrom@sobi.com  jorgen.winroth@sobi.com  ---------------------------------------------------------------------- [i]  World Federation of Hemophilia. Annual Global Survey 2015, published in October 2016. Available at: http://www1.wfh.org/publication/files/pdf-1669.pdf . Accessed on May 23, 2017. [ii]  World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637 . Accessed on May 23, 2017. [iii]  World Federation of Hemophilia. Guideline for the management of hemophilia, 2nd edition. Available at: http://www1.wfh.org/publication/files/pdf-1472.pdf . Accessed on May 23, 2017.

Finnair CEO Pekka Vauramo leaves the company to join Metso Corporation

Finnair Plc         Stock Exchange Release        21 May 2018        at 8.30 a.m. EET Finnair’s CEO, Pekka Vauramo, has given notice of his resignation from the company to join Metso Corporation as their new CEO. He will leave Finnair at the latest in November 2018. The search for Vauramo’s successor starts today. “The Board of Finnair is naturally sad to see Pekka Vauramo leave the company, but we also respect his personal decision to take on another challenge. We thank Pekka for his leadership in the past five years and wish him lots of success in his future role,” says Jouko Karvinen, chairman of Finnair’s board of directors. “During the past few years, Finnair’s people have achieved a remarkable transformation and have turned Finnair into a growth company. We all at Finnair, including the board, will now continue this extensive journey of transformation.” “We have been through a lot at Finnair over the past five years,” says Pekka Vauramo, Finnair’s CEO. “Our strategic focus on growth, customer experience, personnel experience and transformation has been the right choice, and I want to extend my warm thanks to the entire Finnair team for this. I have now been offered to take on one more challenge, and this has not been an easy decision for me to make. I am grateful for having been a part of this change journey, and I am committed to leading Finnair together with my team for the rest of my time at Finnair. Our company’s focus needs to be on the future development of the company every day.”

SaltX receives SunCool breakthrough order

SaltX communicated at the renewable energy conference Ghana in October of last year that it had initiated a collaboration with the energy company SunAct (previously SolarX). SunAct has already purchased a small number of SunCool collectors that are now being installed for demonstration purposes at the institute of industrialization, CSIIR in Accra.  ”This order is important for us on several levels; it accelerates sales in Africa - a key market for SunCool outside of China, and it proves the strength of SunCool as an autonomous and cost efficient solar energy solution. It is also important to show that our technology can make a big difference for many people who today lack basic pre-requisites”,says Karl Bohman, CEO of SaltX Technology. SunAct’s customer – Thermodul Systems – is a German house manufacturer with unique and cost-effective module-based building technology. The company recently signed a $300-million contract with Ghana First that will operate the stations on behalf of Ghana’s government.  ”We are pleased to have SaltX as partner in this important endeavor offering sustainable energy to autonomous sanitation buildings in Ghana. Our ambition is to become Ghana’s leading provider of solar energy solutions, and with our strong collaboration with CSIIR we can access 1,400 installers to implement solar energy systems including SunCool”, says Francis Asante, CEO of SunAct. SunAct is to import SunCool collectors from SaltX and its Chinese partner NSECT but has an option to, after the first 1,000 collectors have been delivered, purchase the core tubes with SaltX material from NSECT, still via SaltX, and then assemble the collectors in Ghana. Om SunActSunAct is a private, newly started energy company in Ghana with the ambition to deliver, install and operate innovative and cost efficient solar energy solutions. The company obtains in connection with this SunCool order an exclusive market right to, during the term of the contract, sell SunCool in Ghana. Om ThermodulThermodul Systems - http://www.thermodulsystem.de– is a manufacturer of a unique and inexpensive module-based building technology that makes it possible to construct buildings in significantly less time than conventional technologies and/or material.   Om SaltX TechnologySaltX Technology - www.saltxtechnology.com- develops and sells patented energy storage technology. Main customers are major global OEM partners and energy companies such as Alfa Laval, Vattenfall, Mobile Climate Control and Rheem. SaltX Technology's share is listed on NASDAQ First North Premier in Stockholm. SaltX Technology’s Certified Adviser is FNCA Sweden AB. For further information, please contact: Karl Bohman, CEO SaltX Technology, tel: +46-705 600 268 ************************************************** SaltX Technology is obliged to disclose this information under the EU Market Abuse Regulation (MAR). The information was provided by the contact person listed above, for publication on May 21, 2018, at 8 am CET.   StockholmMay 21, 2018


Pfizer has informed Karo Pharma that a new milestone has been achieved. This means that Karo Pharma receives a payment of 6 MUSD. In December 2011, Karo Pharma entered a research collaboration and licensing agreement with the American company Pfizer. The aim of this agreement is to discover and develop compounds that inhibit the activity of the nuclear hormone receptor RORgamma, for treatment of autoimmune diseases. The development is lead by Pfizer according to the terms of the agreement. Pfizer has global exclusive rights to use, develop, manufacture and commercialize the compounds and products developed under the agreement, and holds patents relating to the compounds and products developed. Karo Pharma can receive up to 200 MUSD when Pfizer achieves certain development and sales milestones in the project. In addition, Karo Pharma is entitled to royalties on future sales. "We are very pleased to receive this milestone and that the project is moving forward successfully” says Anders Lönner, Chairman of the Board, Karo Pharma.ABOUT KARO PHARMAKaro Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment. The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication on May 21, 2018 at 08.00 CET. This press release is also available on www.newsroom.cision.com.FORWARD-LOOKING STATEMENTSThis news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Karo Pharma. Such forward-looking statements reflect our current expectations and are based on the information currently available. Karo Pharma cannot give any assurance as to whether such forward-looking statements will prove to be correct. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Net Gaming completes acquisition of assets in the DACH region

On April 19, 2018, Net Gaming announced the signing of a Letter of Intent to this effect. Net Gaming has now signed an agreement to acquire these affiliate assets.The operations show strong growth and are currently generating quarterly sales of approximately EUR 200,000, with an operating margin of approximately 75%. About 75% of the revenues are generated via revenue sharing. “The acquisition strengthens our position in the DACH region. We have identified the DACH region as one of the geographical markets with the highest growth potential in the long run. This transaction will give us further opportunities to grow our existing operations in the region, and also expand these assets to new markets. Considering the fact the the founders will remain and continue to work with the assets for Net Gaming feels truly great, since we have got a great first impression of the said founders,” comments Marcus Teilman, CEO of Net Gaming. "We are truly excited at finding the right buyer for our business, and are looking forward to work with the team at Net Gaming to take the websites to the next level. With its proven track record and a group of savvy people around, Net Gaming takes a great leap forward to become a major player in performance marketing on the DACH market." comments André Boeck, founder and CEO of Webwiser. The initial purchase consideration of EUR 2.29 million will be settled with existing cash resources. Payment of a maximum aditional consideration of EUR 1.25 million may also be required. The acquired assets from Webwiser will be consolidated immediately and will have a positive impact of Net Gaming's profit. For further information, please contact:Marcus Teilman, President and CEO+356 9936 7352 Net Gaming Europe AB (publ)                 Telephone: +46 8-410 380 44E-mail: info@netgaming.seWebsite: www.netgaming.se The information in this press release is information that Net Gaming Europe AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation and, where applicable, the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was provided by the contact person above for publication on 21 May 2018 at 08.30 CET.  About Net Gaming Net Gaming owns, operates and develops high-quality online comparison sites for the purpose of channelling user traffic to the Company’s customers – primarily iGaming operators. Within the Group, approximately 130 comparison sites are operated in 30 countries. Net Gaming generates valuable user traffic through the sites, mainly to global iGaming operators. The Company was founded in 2005, has over 80 employees and is headquartered in Malta. The share (NETG) is listed on AktieTorget.

Cantargia receives Notice of Allowance from USPTO for the antibody CAN03

Cantargia develops antibody based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The lead project CAN04 is currently in clinical development for treatment of non-small cell lung cancer and pancreatic cancer. A second project, CANxx, is in preclinical phase with the aim to develop an antibody against IL1RAP for treatment of autoimmune/inflammatory diseases. One antibody, CAN03, originally developed as a backup candidate for CAN04, modifies IL1RAP signaling in a unique way and has additionally demonstrated interesting IL-33 blocking properties. CAN03 is included in the CANxx discovery program. The USPTO has now notified Cantargia that a notice of allowance for Cantargia’s patent application 15/501,710 has been issued. This patent application includes the antibody CAN03. In essence, this means that the USPTO intends to grant the patent after certain formal steps has been completed. If granted, the patent is valid until 2035. “We are very pleased that the USPTO intends to grant a patent for our antibody CAN03. This antibody has unique properties in that it blocks signaling from both IL-1 and IL-33, a combination that may be highly relevant for the treatment of inflammatory and autoimmune diseases. This patent application is an important component of the IP portfolio around our CANxx project”, Göran Forsberg, Cantargia’s CEO says. For further information, please contact Göran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This constitutes information that Cantargia AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 21 May 2018, at 8:30 a.m. About Cantargia Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 antibody targeted at IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases. Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

St1 and SCA form partnership to produce renewable fuels

The aim of the partnership is to construct a new facility to produce advanced renewable fuels from tall oil with a capacity of 100 000 tonnes per annum. Construction of the new facility, subject to permission process and final approval from both companies, is expected to cost around 500 MSEK to build and is planned to be operational in 2021. Tall oil is a residual product from the production of kraft pulp in SCA’s mills Östrand, Obbola and Munksund. SCA is presently expanding its kraft pulp mill Östrand and as a result the production of tall oil from the mill will increase by more than 100 per cent. Between the two partners, the parties constitute the full value-chain from the raw material to the refining process, distribution and sale of the renewable fuel to the customers. "Partnership with SCA is a key element in implementation of our renewable fuels investment program and it secures supply of raw materials to meet the ambitious Nordic climate targets for 2030," says Mika Anttonen, Chairman of the Board of St1. “SCA works with a number of interesting development projects in renewable energy, and we see interesting opportunities to further develop the cooperation.” "When we start working on more refined energy products, partnership with a company that knows the processes and the market, is very valuable," says Ulf Larsson, President and CEO of SCA. “St1 is a company with the ambition to work with us in the change towards renewable fuels.” For further information, please contact Björn Lyngfelt, SVP Communications SCA, tel. +46 60 19 34 98Mikael Källgren, President Renewable Energy SCA, tel. +46 60 19 33 17Bo-Erik Svensson, CEO St1 Refinery, tel. +46 31 744 6250, bo-erik.svensson@st1.se  St1 Nordic Oy is a Nordic energy group whose vision is to be the leading producer and seller of CO2-aware energy. The Group researches and develops economically viable, environmentally sustainable energy solutions. St1 focuses on fuels marketing activities, oil refining and renewable energy solutions such as waste-based advanced ethanol fuels and industrial wind power. The Group has 1400 St1 and Shell branded retail stations in Finland, Sweden and Norway. Headquartered in Helsinki, St1 employs currently more than 750 people. www.st1.eu  The core of SCA’s business is the forest, 2.6 million hectares in northern Sweden. Around this unique resource, we have built a well-developed value chain based on renewable raw material from our own and others’ forests. We offer paper for packaging and print, pulp, wood products, renewable energy, services for forest owners and efficient transport solutions. 2017 the forest products company Svenska Cellulosa Aktiebolaget SCA (publ) had approximately 4,000 employees and sales amounted to approximately SEK 16.7 bn (EUR 1,6 bn). SCA was founded in 1929 and has its headquarters in Sundsvall, Sweden. More information at www.sca.com.

Ericsson Expert Analytics selected by EE to improve customer experience

Ericsson (NASDAQ: ERIC) has been selected by EE, the UK’s largest mobile operator and part of the BT Group, to deliver a next-generation customer experience management (CEM) system based on Ericsson Expert Analytics . The multi-year agreement includes software, implementation services and IT Managed Support services. The solution will support multiple services, including 2G, 3G, 4G, VoLTE and VoWiFi, and is aimed at improving subscriber satisfaction, net promoter score, propensity to call and first call resolution rate. Dave Salam, EE Director of Mobility and Analytics, says: “With Ericsson Expert Analytics supporting our new customer experience management capability, we will be better able to understand our customers’ experience in real-time, and the detailed insights provided will help us keep improving network quality.” Arun Bansal, Senior Vice President and Head of Market Area Europe and Latin America, Ericsson, says: “This is another significant milestone in our relationship with EE and an important deal for us in the field of IT. The introduction of Ericsson Expert Analytics will enable more effective customer care and service operations, allowing EE to proactively resolve issues before they have an impact on subscriber satisfaction.” Ericsson Expert Analytics will measure the perceived customer experience for each subscriber, providing actionable insights based on data collected in real-time from network elements and probes, as well as from operations and business support systems. NOTES TO EDITORS For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson Subscribe to Ericsson press releases here . MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) ABOUT ERICSSON Ericsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com ABOUT EE EE, part of BT Group, is the largest and most advanced mobile communications company in the UK, delivering mobile and fixed communications services to consumers. EE runs the UK's biggest and fastest mobile network, offering superfast 4G in more places than any other operator after pioneering the UK's first superfast 4G mobile service in October 2012. Today, EE has more than 600 shops across the UK, and EE's 4G coverage extends to more than 90% of the UK’s landmass. EE has received extensive independent recognition, including being ranked the UK's best overall network by RootMetrics®; Best Network for five years in a row at the Mobile Choice Awards; Best Network at the 2015, 2016 and 2017 Mobile News Awards; Best Consumer Network at the 2015, 2016 and 2017 Mobile Industry Awards; as well as Fastest Network and Best Network Coverage at the 2017 uSwitch Mobile Awards. Find us: Facebook at: facebook.com/ee Twitter at: twitter.com/ee YouTube at: youtube.com/ee 

Siemens partners with Clean Motion to enable innovative digitalization journey

Siemens announced today a new partnership with Clean Motion AB, manufacturer of the electric vehicle Zbee, which will help enable Clean Motion to build and maintain a digital master factory using Siemens’ technology and solutions. Clean Motion has a global expansion strategy based on distributed local manufacturing in many smaller factories close to the end customer. To succeed in such an expansion, it is important to ensure a digitally defined product and manufacturing process together with a centrally controlled supply chain. Clean Motion is now taking the next step in its digitalization process with Siemens PLM Software to reach fully digital twins of both the product, the manufacturing process and the factory. As part of the digitalization strategy, a digital master factory will be built with Siemens’ product lifecycle management (PLM) software. This factory will then allow adjustments for the introduction of new variants and optimization of production flows. Clean Motion will be able to build a large number of independent physical plants and help ensure they operate in exactly the same way worldwide, by using Siemens PLM Software solutions that will maintain and manage the digital twin mirroring the Clean Motion digital master factory. Clean Motion plans to deploy Mindsphere, the cloud-based open Internet of Things (IoT) operating system from Siemens, powered by Amazon Web Services (AWS), to enable the connected factory and create a closed loop process that monitors and feeds back live data from usage and factory to further optimize Clean Motion’s business and process. "The use of Siemens’ solutions for IoT will provide opportunities to record how the product is produced and used in real time,” said Göran Folkesson, CEO of Clean Motion. “With this information we can optimize our existing business model but also develop new business opportunities. This also means that we will be able to return information about usage and manufacturing, ensuring that we are constantly building with the same high quality throughout the world.” Clean Motion’s business model is based on a central purchasing and logistics organization with local production units building, servicing and providing Zbee on the local market. The goal is that each micro factory will have an annual capacity of approximately 5,000 vehicles. The concept is based on the fact that each micro factory contains all parts for the entire vehicle's life cycle, where production, sales and aftermarket are aggregated. Clean Motion will make use of Siemens’ NX™ software, a leading integrated solution for computer-aided design, manufacturing and engineering (CAD/CAM/CAE), the Teamcenter®portfolio, the world’s most widely used digital lifecycle management software, the Simcenter™ portfolio, a robust suite of simulation software and test solutions, and the Tecnomatix®portfolio, the industry-leading digital manufacturing software solutions to build and maintain the digital twin. Clean Motion will also use Siemens’ Managed Services with Teamcenter on the cloud, powered by AWS, with a goal to have an end-to-end industrial software solution on the cloud. "We will create a closed system with a network of centrally controlled production units. This would not have been possible without a partner like Siemens," said Niklas Ankarkrona, chairman, Clean Motion. "Clean Motion’s business model provides a solid base for their digitalization journey, and our software provided as a hosted cloud service on AWS can give the end-to-end solution necessary for their critical next steps,” said Mats Friberg, CEO, Siemens PLM Software, Sweden. “Collaborating with companies such as Clean Motion allows Siemens to achieve a high level of innovation and realization of these new technologies in combination with already developed working methods.” The collaboration will not be limited to the factory. Zbee is already building a virtual product, and with the Siemens PLM software portfolio, Clean Motion will build a digital twin of the product, process and factory, enabling even greater opportunities to simulate, optimize and verify both product and production. Using the digital twin, Clean Motion will be able to simulate the vehicle's entire life cycle before it is completed. For further information on the digital twin and Siemens’ PLM portfolio, please see https://www.plm.automation.siemens.com/global/en/. Siemens PLM Software, a business unit of the Siemens Digital Factory Division, is a leading global provider of software solutions to drive the digital transformation of industry, creating new opportunities for manufacturers to realize innovation. With headquarters in Plano, Texas, and over 140,000 customers worldwide, Siemens PLM Software works with companies of all sizes to transform the way ideas come to life, the way products are realized, and the way products and assets in operation are used and understood. For more information on Siemens PLM Software products and services, visit www.siemens.com/plm. Contact for journalists Natalie NavalesPhone: +1 314 264 8671;E-mail: Natalie.Navales@siemens.com Johan NybomPhone: +46 73 660 81 75E-mail: Johan.Nybom@inmema.com Follow us on Twitter at: www.twitter.com/siemens_press Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for 170 years. The company is active around the globe, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is a leading supplier of efficient power generation and power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2017, which ended on September 30, 2017, Siemens generated revenue of €83.0 billion and net income of €6.2 billion. At the end of September 2017, the company had around 377,000 employees worldwide. Further information is available on the Internet at www.siemens.com. Note: Siemens, the Siemens logo and Simatic IT are trademarks or registered trademarks of Siemens AG. Teamcenter, NX and Tecnomatix are trademarks or registered trademarks of Siemens Product Lifecycle Management Software Inc. or its subsidiaries in the United States and in other countries. Simcenter is a trademark or registered trademark of Siemens Industry Software NV or any of its affiliates. All other trademarks, registered trademarks or service marks belong to their respective holders.

NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development

Review of the topline phase I data shows that KL1333 has a highly favourable and very clear dose-proportional pharmacokinetic (PK) profile. There were no serious adverse events (SAEs), and only mild gastrointestinal adverse events (AEs) were recorded at higher doses. Based on the positive PK and safety results NeuroVive is moving rapidly to initiate the next study in Europe that will include repeated dosing (multiple ascending dose; MAD) in healthy volunteers and patients. Detailed analysis of the complete data set is ongoing. There is a huge unmet medical need for medicines that treat genetic mitochondrial diseases. Patients can have severe symptoms in any organ and have significantly reduced life-expectancy. These diseases are rare diseases for which there are almost no registered medicines. “We are very excited about the results from the first in human clinical trial of KL1333 and see them as clearly promising for the continued clinical development of this important program together with NeuroVive,” commented Yungjin Pharm CEO & President Chae J. Lee. NeuroVive will now, together with a leading global contract research organization (CRO), rapidly progress the planning and preparation of the phase I MAD study of KL1333 in healthy volunteers and genetic mitochondrial disease patients. The study is expected to commence in the second half of 2018. “With the convincing safety profile of KL1333 and favorable PK data, we will confidently bring this promising program forward in development with the highest priority. The next important step is the clinical phase I MAD study, which will take us further towards the goal of offering a novel treatment to patients with severe genetic mitochondrial disease with few or no treatment options,” said NeuroVive CEO Erik Kinnman. The MAD study will consist of two parts; a dose escalation in healthy volunteers, and also multiple dosing of patients with genetic mitochondrial disease. The purpose of the study is to further investigate safety and pharmacokinetics of KL1333 prior to initiating a phase II efficacy clinical trial. The study will be conducted at sites in the UK and results are expected in the first half of 2019. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 11:00 a.m. CEST on 21 May 2018. For more information please contact: Daniel Schale, Director of Communications +46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@neurovive.com, www.neurovive.com About the KL1333 SAD study The study is a dose block-randomized, double-blind, placebo-controlled, single-dose, dose-escalation, phase I clinical study. 25 ,50, 100, 400, 600, 800 mg of KL1333 was administered in 60 healthy volunteers to investigate pharmacokinetics, safety and tolerability. About KL1333 KL1333 is a potent modulator of the cellular levels of NAD+, a central coenzyme in the cell’s energy metabolism. KL1333 has in preclinical models been demonstrated to increase mitochondrial energy output, reduce lactate accumulation, diminish the formation of free radicals, and to have long-term beneficial effects on energy metabolism such as the formation of new mitochondria. It is in clinical development stage intended to document the use for chronic oral treatment in primary genetic mitochondrial disorders such as MELAS, KSS, PEO, Pearson and MERRF. KL1333 is currently being evaluated in clinical phase I-studies and has been granted orphan drug designation in both the United States and Europe. About genetic mitochondrial disease Genetic mitochondrial diseases are metabolic diseases that affect the ability of cells to convert energy. The disorders can manifest differently depending on the organs affected by the genetic defects and are viewed as syndromes. An estimated 12 in every 100,000 people suffer from a mitochondrial disease. Mitochondrial diseases often present in early childhood and lead to severe symptoms, such as stunted growth, heart failure and rhythm disturbances, dementia, movement disorders, stroke-like episodes, deafness, blindness, droopy eyelids, limited mobility of the eyes, vomiting and seizures. About NeuroVive  NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). About Yungjin Pharm Yungjin Pharm Co. Ltd., established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the inspiring mission statement, "To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products", they have shown a successful contribution not only within Korea, but also through global expansion. As a result, they have received a total of 25 awards including the President Award for Superior Product Development, the Prime Minister Award, Industry Award and many more. These accomplishments demonstrate their sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments. The company is listed on the South Korean stock market, KOSPI (KRX 003520).

Information in the Swedish media regarding a supervisory matter within Handelsbanken’s UK branch

Swedish media are today reporting on a matter relating to the Swedish Financial Supervisory Authority’s supervision of Handelsbanken’s UK operations. Among other things, this matter relates to questions that the Bank previously discussed and reported in its Pillar 3 Report, which was published in February 2018.  It is important to emphasise that, in the Bank’s assessment, the observations made by the Supervisory Authority do not infer an increased risk of loan losses within Handelsbanken UK. This supervisory matter concerns, for example, how decision data for risk rating in the Bank’s IRB models and credit decisions is set out and documented.  In the UK, Handelsbanken applies the same strict credit process and risk tolerance level as in the Group as a whole. Over the decades, these methods, together with our decentralised business model, have resulted in Handelsbanken maintaining significantly lower loan losses than its peers. For a while now, there has been an ongoing dialogue between the Bank and the Swedish Financial Supervisory Authority. The purpose of this is to ensure that the Bank can make the improvements expected by the Authority in the best possible manner. In recent years, the Bank has taken measures to improve its procedures, processes and documentation of decision data, and its risk rating of credits.  The Bank’s actual loan losses are lower than the levels that have been estimated by the Bank’s Internal Risk-Based approaches (known as IRB models), which shows that Handelsbanken has satisfactory margins.  In addition, extensive annual validations of the Bank’s IRB models are carried out by the Bank’s unit for Independent Risk Control. One aim of this is to ensure that the models are used correctly and consistently throughout the Bank.  A letter from the Authority of the type referred to in the media is a standard part of a supervisory relationship. The aim is to enable the Bank to do fact-checking and submit its opinions. In other words, the letter does not constitute the final position of the authority.For further information, please contact:Mikael Sörensen, CEO Handelsbanken UK, + 46 8–22 92 20Katarina Grönwall, Chief Communications Officer +46 72–203 32 63Lars Höglund, Head of Investor Relations +46 8–701 51 70, +46 70–345 51 70Johan Wallqvist, Head of Group Media Relations, +46 8–701 80 47,+46 72–206 34 50For more information about Handelsbanken, see: www.handelsbanken.com  

Autoliv provides update on planned Veoneer spin-off

Veoneer, Inc. has filed an amendment to its Registration Statement on Form 10 with the U.S. Securities and Exchange Commission (SEC) in connection with its planned spin-off from Autoliv. The amendment includes unaudited pro forma condensed combined financial statements which illustrate the financial impacts of the spin-off and related transactions, financial information of Veoneer for the first quarter of 2018 and information regarding certain expected directors of Veoneer following completion of the spin-off. The amendment to the Form 10 further specifies that related to the spin-off, Autoliv intends to provide total cash liquidity of approximately $1 billion (funded through a mixture of new external funding and existing cash). Autoliv’s Board had previously instructed management to assess Veoneer’s total cash liquidity needs of up to $1.2 billion. The unaudited pro forma condensed combined financial statements have been derived from the historical combined financial statements and the unaudited condensed combined interim financial statements of Veoneer with adjustments meant to give effect to the spin-off and related transactions. The unaudited pro forma condensed combined financial statements are for informational purposes only and do not purport to represent what Veoneer’s financial position and results of operations actually would have been had the spin-off and related transactions occurred on the dates indicated, or to project Veoneer’s financial performance for any future period. A copy of the registration statement is available for review at www.sec.gov under the name Veoneer, Inc. https://www.sec.gov/Archives/edgar/data/1733186/000119312518168532/0001193125-18-168532-index.htm Trading in Veoneer common stock and Swedish Depository Receipts is anticipated to begin in the early part of the third quarter of 2018 with listings on the New York Stock Exchange and Nasdaq Stockholm, respectively. Inquiries:  Media: Thomas Jönsson, Corporate Communications,   Tel +46 (0)8 5872 0627 Investors & Analysts: Anders Trapp, Investor Relations, Tel +46 (0)8 58 72 06 71 Investors & Analysts: Ray Pekar, Investor Relations, Tel, +1 (248) 794 4537 About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 72,000 employees in 27 countries. In addition, the Company has 23 technical centers in nine countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2017 amounted to about US $10.4 billion. The Company’s shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at www.autoliv.com. Safe Harbor Statement This release contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future, including those related to the intended spin-off of Autoliv’s Electronics business, the timing of such spin-off, whether the spin-off is ultimately consummated, the timing and amount of the capital injection into Veoneer and the expected performance of Autoliv and Veoneer following completion of the spin-off. All forward-looking statements are based upon our current expectations, various assumptions and/or data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any forward-looking statements in light of new information or future events, except as required by law.

Talkpool launches Nordic IoT Networks

This initiative is targeted to meet the increasing customer demand for IoT connectivity fueled by the growing number of IoT projects and sensors deployed.  “LoRa is a low power wide area network radio technology, optimized for very long range and millions of connected devices at low cost. This enables solutions that previously were not economically viable or even possible” says Stefan Lindgren, CTO of Talkpool.  Phase one of the network roll out is already in progress and will provide coverage in the regions of Stockholm, Gothenburg, Malmoe/Lund and Uppsala. Subsequent phases will provide coverage across Sweden, Norway and Denmark.   “The Nordic countries continue to be at the global forefront of the IoT. The average number of connected things per person in the region is expected to be four times as many as in the rest of the world by 2021. We believe that coverage provided by Nordic IoT Networks combined with the collaborative business model will further boost the Nordic IoT market” adds Mats Björs Chairman of the Niot Board.  Niot will build and operate a LoRa network but also cooperate with other network operators to consolidate and extend the network coverage. All network access will however be provided by partners. Talkpool will be the first solution provider and more partner companies are soon to follow.  “We have a lot of interesting projects in our pipeline - soon to be announced and they all need LoRa connectivity concludes” Stefan Lindgren, CTO of Talkpool.  Talkpool will also be a minority owner of Nordic IoT Networks and provide LoRa network expertise and manage the roll out while the investor group will finance the company.  For more information: Henrik LindgrenCEO Nordic IoT Networkshenrik.lindgren@niotnet.com About TalkpoolTalkpool provides IoT solutions and telecommunication network services globally. Through its cutting-edge technical expertise, long experience and agile business model, Talkpool offers global telecom vendors and operators high-quality services on short notice no matter the location. Moreover, Talkpool is one of few companies with actual solutions and contracts in place in the exciting IoT-market. Remium Nordic Holding AB is Talkpool’s Certified Advisor. www.talkpool.com This information is inside information that Talkpool AG (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.00 CET on May 21, 2018.

Kappahl becomes a member of the Sustainable Apparel Coalition

Swedish fashion chain KappAhl has decided to become a member of the Sustainable Apparel Coalition to help speed up the pace of change in sustainable working methods and solutions in the fashion industry. As part of the SAC, we can work with other players in the industry - purchasers, suppliers, researchers, investors and consumers - to coordinate efforts to achieve greater transparency and better results in moving the fashion industry towards a more sustainable future.  KappAhl is now in the process of developing their working methods using the SAC’s Higg Index suite of tools. The goal is to set clear standards for the entire industry to measure and assess the sustainability performance of suppliers and products.      “A harmonised approach within the industry will have a positive impact on our entire value chain and bring greater transparency to the industry. This is the route to achieving a sustainable fashion industry,” says Fredrika Klarén, Head of Sustainability at KappAhl.   Sustainable Apparel Coalition (SAC) is an organisation working to create a sustainable fashion industry with the vision of an industry that causes no harm to the environment and has a positive impact on people and society. SAC’s Higg Index is a suite of tools designed to measure and assess the sustainability performance of suppliers and products and promote long-term sustainable improvements for factory workers, local communities and the environment. Through harmonised working methods and processes, the industry will also provide the transparency that is increasingly being demanded by consumers. More info: www.apparelcoalition.org 

Stora Enso accelerates growth in renewable materials by co-operating with the startup Sulapac

Through the joint development agreement, Stora Enso will licence Sulapac’s materials and technology, and begin the development of fully renewable caps and closures for liquid packages. Other areas for joint development work include food packages and packages for consumer electronics.  “At Stora Enso we believe that everything that’s made with fossil-based materials today can be made from a tree tomorrow. Our future growth comes from innovations in renewable materials,” says Annica Bresky, EVP Consumer Board at Stora Enso. “With our partners, such as Sulapac, we drive these innovations to create the packaging of the future.” “The World needs material solutions that are one hundred percent biodegradable. Sulapac material has all the benefits of plastic yet it completely biodegrades without the issues of microplastic. With Stora Enso’s global expertise we can really speed up the global launch of our Sulapac material,” says Suvi Haimi, Sulapac CEO. The cooperation between the companies began in 2017 through Stora Enso’s Accelerator programme, which involves partnering with Aalto University and start-ups to ideate and innovate around renewable products. Stora Enso is the first customer to use Sulapac’s material and technology license. About SulapacSulapac is a fully biodegradable and microplastic free material made of renewable and sustainable raw materials. Sulapac products are designed for brands that want to eliminate plastic waste and demonstrate a genuine commitment to sustainability through the use of premium ecological material. The company was founded in 2016 by Suvi Haimi and Laura Kyllönen and is based in Helsinki, Finland. sulapac.com   For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228 Part of the bioeconomy, Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper globally. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2017 were EUR 10 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

NeuroVive Pharmaceutical AB Interim report January – March 2018

Business operations Important events January – March 2018 · NeuroVive decided to conduct a rights issue for the continued development of the company’s drug projects following shareholder approval at an Extraordinary General Meeting. · The company reported positive efficacy data in an experimental model, entailing a breakthrough for the NVP025 mitochondrial myopathy project. · NeuroVive presented the company at the Stockholm Corporate Finance Life Science Seminar. · The company presented its NASH research at the 2nd Annual H.C. Wainwright NASH Investor Conference. Important events after the end of the period · NeuroVive conducted an oversubscribed rights issue. · The company announced that the last patient had been recruited to the first KL1333 Phase I clinical study. · KL1333 was granted orphan drug designation by the FDA in the US. · NeuroVive announced a collaboration with TRACK-TBI, a network of world-class traumatic brain injury (TBI) researchers. · NeuroVive held Annual General Meeting on 27 April in Lund, Sweden. · NeuroVive and Yungjin reported positive KL1333 phase I clinical study results, paving the way for further clinical development. Financial information  First quarter (January – March 2018)  · Net revenues were SEK 0 (27,000) and other operating income was SEK 174,000 (63,000) · Loss before tax was KSEK -13 053 (-21 390) · Loss per share* was SEK -0,25 (-0,40) · Diluted loss per share** was SEK -0,25 (-0,40) * Profit/loss for the period divided by average number of shares before dilution at the end of the period. ** Profit/loss for the period divided by average number of shares after dilution at the end of the period Please find the complete interim report attached below. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 22 May 2018. For more information please contact: Daniel Schale, Director of Communications +46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@neurovive.com, www.neurovive.com About NeuroVive  NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

Dignitana publishes Interim Financial Report for Q1 2018

The complete Q1 2018 Interim financial report is attached to this press release and may also be downloaded from the company website at http://www.dignitana.se/rapporter/ Interim Report – Summary ­­ Key RatiosDignitana Group Q1 2018 Q1 2017 Full Year 2017 Net revenues, TSEK                     6,127            22,941   5,897Total revenues TSEK                     6,177            23,133   5,988Net profit after                   (8,109)            (42,355)financial items, TSEK (8,950)Cash and bank balances,                   17,995              1,018TSEK 22,185Earnings per share -0.2 -0.4 -2.1before and afterdilution, SEK Dignitana AB Q1 2018 Q1 2017 Full Year 2017 Net revenues, TSEK                     5,312            18,300   4,444Total revenues TSEK                     5,362            18,490   4,535Net profit after                   (8,189)            (42,277)financial items, TSEK (9,027)Cash and bank balances,                   17,762                606TSEK 19,636 Significant events during the period ·  The DigniTherm™ Click Cap was introduced to facilities in December 2017 and the roll-out to all U.S. facilities was completed in Q1 2018. ·  13 machines were installed at 12 sites in the US in Q1. ·  Transition of operations from Lund, Sweden to the U.S. was announced and initiated in Q4 2017 and continued in Q1. It was successfully completed in April, two months ahead of schedule. Dignitana AB remains in Lund. ·  The Rights offering which was begun in Q4 2017 was fully subscribed and funding was completed in early January 2018. ·  At an Extraordinary General Meeting 16 March 2018 Thomas Kelly, Ingrid Atteryd Heiman, and Mikael Wahlgren were appointed to the Board of Directors with Thomas Kelly designated as Chairman of the Board for Dignitana AB. ·  In March James McKinney was named President and COO of Dignitana, Inc. ·  In March Dignitana initiated an application with the American Medical Association for a unique CPT Code for scalp cooling to provide a pathway for universal scalp cooling coverage. The decision will be announced by the AMA in June. Significant events after the first quarter · Thomas Kelly, Bill Cronin, Ingrid Atteryd Heiman, and Mikael Wahlgren were re-elected to the Board of Directors at the Annual General Meeting 24 April 2018 with Thomas Kelly as Chairman. ·  In April Dignitana announced the transfer of management of all European installations of DigniCap from Sysmex to Dignitana. ·  Contracts for 4 locations have been signed since 1 April 2018 representing 4 machines. ·  Agreed to expand unit locations with Florida Cancer Specialists. ·  Contracted with Atlantic Health System to provide scalp cooling services. ·  Dignitana initiated its first direct-to-customer lease unit lease transaction for two locations in Spain. To download the full report, go to http://www.dignitana.se/rapporter/ This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 09:00 (CET), 22 May 2018. 

European patent approval for Episurf Medical’s individualised surgical instruments

The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent being approved is within the area of individualised surgical instruments with a focus on the drill guide for the Episealer® Femoral Twin implant. This is the first patent approval within this patent family. “This patent covers the drill guide for the Episealer® Femoral Twin implant, which is the implant that shows the highest sales volumes. Extensive IP protection within this field is therefore important for us”, comments Pål Ryfors, CEO, Episurf Medical.   For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.00 CEST on 22 May 2018.

Eagle Filters awarded Excellent Gas Turbine Filtration Technology Innovation of the Year Award at the 5th China Gas Turbine Focus Conference

The Gas Turbine Focus Awards Ceremony celebrates the leading enterprises in China and beyond. It’s also an appeal to encourage the new rising and promising companies.  China is a potentially significant market for Eagle Filters’ technology. The total electricity produced by Combined Cycle Gas Turbine (CCGT) plants in China is estimated to be 188 TWh, which presents a significant opportunity for Eagle Filters in the Chinese market. Eagle Filters has already proven that it can provide significant fuel savings and efficiency gains for gas power plants in other markets such as the US and Europe. Their filtration solutions are compatible with the majority of filter housings already in place at CCGT’s, so they can be deployed without the need for changes on the part of gas turbine managers. To provide an example of Eagle Filters’ potential in China, their technology could provide 3.2 million MWh of extra production (equivalent of two large power plants); 8 million GJ fuel savings (or 200 million m3of natural gas); and 450 000 tons of CO2 prevented if it were rolled out in all CCGT. Loudspring CEO Lassi Noponen: “Eagle Filters is a great example of a Loudspring company saving natural resources, in Eagle’s case natural gas. Eagle Filters supplies industry leading products to the energy industry and helps them save enormous amounts of fuel and thus reduce CO2 emissions. Saving a valuable resource like natural gas and optimizing its use is good for business and the planet”. Eagle Filters Vice-President Frank Vranken: “The 5th China Gas Turbine Focus Conference was a great opportunity to present our clean technology to a forum of scientific institutions, researchers and users of gas turbines. Being awarded as an innovative technology at this event only confirms our role as a leader and pioneer in China. Such acknowledgement motives us to do better day after day at Eagle Filters.” For more information about Eagle Filters and their technology please contact Frank Vranken at: frank.vranken@eaglefilters.fi

Cherry’s CEO under investigation by Swedish Economic Crime Authority

During the morning, the Swedish Economic Crime Authority has performed a search at the head office of Cherry AB and in relation to this event, the company’s CEO, Anders Holmgren, was arrested. Cherry will fully cooperate with the Economic Crime Authority in the investigation. During the period of the investigation, Gunnar Lind, chairman of the Cherry Audit Committee, will be acting CEO of Cherry. Cherry will return with more information as soon as more details can be presented.For further information, please contact:Morten Klein, Chairman of Cherry AB, +47 913 22 222, morten@kleingroup.noAnders Antonsson, IR & Communications: +46 709 994 970, anders.antonsson@cherry.se This information is information that Cherry AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on 22 May 2018, at 2:30 p.m. CET. CHERRY IN BRIEF Cherry is a Swedish innovating and fast-growing company with operations in gaming, entertainment and media. The company was established in 1963 and today operates through five diversified business areas: Online Gaming, Game Development, Online Marketing, Gaming Technology, and Restaurant Casino. The objective is to grow organically in combination with strategic acquisitions of fast-growing companies. Cherry employs some 1,400 people and has about 6,700 shareholders. The company’s class B share is listed on the Nasdaq Stockholm exchange, Mid Cap segment. More information is available at www.cherry.se.

Active dialogues on six continents

Enviro's projects and dialogues around the world. The need for advanced technology combined with tried-and-true, verified commercial in-service experience is increasing in step with a multitude of trends. But that need is also thrown into sharp relief because alternative technologies and simpler solutions are quite simply not meeting the quality requirements dictated by the market. EnviroCB is. “We are starting from a completely unique position compared to most other actors. At this point, Enviro has already provided industrial-quality recovered carbon black for rubber components in Volvo’s passenger cars for two years.” Thomas Sörensson notes. Several countries have even implemented or have plans to introduce manufacturer liability for waste categories that clearly impact the environment and society, not least tyres. This will generate even more awareness of Enviro’s recycling technology among industry actors around the world. Sörensson continues, “In addition to our recycled materials’ obvious environmental benefits, they’ve been demonstrated to be on a par with virgin carbon black across a wide range of applications and compounders. Considering that the global market for carbon black is estimated to exceed 25 billion dollars by 2020, the potential for both Enviro’s technology and our recycled materials is inarguable.” For more information, please contact:Thomas Sörensson, CEO of Enviro, tel: +46 (0)735-10 53 43, thomas.sorensson@envirosystems.se   Alf Blomqvist, Chairman of the Board, Enviro, tel: +46 (0)733 149 700, alf@blomqvistunlimited.com Scandinavian Enviro Systems AB Regnbågsgatan 8C 417 55 Gothenburginfo@envirosystems.se www.envirosystems.se

Nitro Games announced new game Heroes of Warland

“We are thrilled to announce Heroes of Warland. Our team is taking competitive multiplayer on mobile to a new level with this game. There’s a good market opportunity for a team based competitive multiplayer game on mobile right now. Our hero based class system is a unique new thing in the emerging shooter genre on mobile and helps us to build better team gameplay.” says Jussi Tähtinen, CEO & Co-Founder, Nitro Games Oyj. This launch follows Nitro Games’ strategy where the company is building a portfolio of games to be self-published in the western markets and accessing other markets via publishing partners. Heroes of Warland is the second game in Nitro Games’ new portfolio, following Medals of War that was introduced last year. It has been developed with Nitro Games’ MVP –process, where the game development is closely tied to continuously collecting actual market data and community feedback, as the game is being further developed. This announcement is the first step in the game launch in western markets. After this announcement, the game will soon enter the so-called public soft launch in selected markets. The commercial hard launch is targeted for 2018 after the soft launch. Heroes of Warland is a team-based competitive multiplayer game on mobile. With Heroes of Warland, Nitro Games is introducing hero-based shooter game on mobile for the first time. This genre has been highly popular on PC. Hero-based shooter means that the game has several hero characters, each with own unique skills and abilities, offering a unique and fun team multiplayer experience previously unseen on mobile. Find out more: https://youtu.be/nkYlAO8Gy_8 www.heroesofwarland.com